<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0"><channel><title><![CDATA[NeurotechMag]]></title><description><![CDATA[Keep up with latest in Neurotech 🧠 Weekly newsletter featuring science, research, business and more]]></description><link>https://www.neurotechmag.com</link><image><url>https://substackcdn.com/image/fetch/$s_!X9TQ!,w_256,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F839c2bdf-3399-49b4-819a-e72bb5fa0d4b_256x256.png</url><title>NeurotechMag</title><link>https://www.neurotechmag.com</link></image><generator>Substack</generator><lastBuildDate>Sun, 22 Nov 2026 06:35:43 GMT</lastBuildDate><atom:link href="https://www.neurotechmag.com/feed" rel="self" type="application/rss+xml"/><copyright><![CDATA[NOOCON]]></copyright><language><![CDATA[en]]></language><webMaster><![CDATA[neurotechhub@substack.com]]></webMaster><itunes:owner><itunes:email><![CDATA[neurotechhub@substack.com]]></itunes:email><itunes:name><![CDATA[NOOCON]]></itunes:name></itunes:owner><itunes:author><![CDATA[NOOCON]]></itunes:author><googleplay:owner><![CDATA[neurotechhub@substack.com]]></googleplay:owner><googleplay:email><![CDATA[neurotechhub@substack.com]]></googleplay:email><googleplay:author><![CDATA[NOOCON]]></googleplay:author><itunes:block><![CDATA[Yes]]></itunes:block><item><title><![CDATA[How to Fall Asleep Faster: 5 Neuroscience-Backed Tricks Plus the Gadgets That Support Them]]></title><description><![CDATA[Body temperature, evening light, breathing, imagery and sound each have a mechanism behind them, and the gadgets built on top of those mechanisms are at very different stages of proof.]]></description><link>https://www.neurotechmag.com/p/how-to-fall-asleep-faster-5-neuroscience</link><guid isPermaLink="false">https://www.neurotechmag.com/p/how-to-fall-asleep-faster-5-neuroscience</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Fri, 20 Nov 2026 17:41:07 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!eVhE!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!eVhE!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!eVhE!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!eVhE!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!eVhE!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!eVhE!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!eVhE!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2385374,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/223059137?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!eVhE!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!eVhE!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!eVhE!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!eVhE!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47f00529-73f9-40fe-9e28-26d51c225c41_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Falling asleep is partly an alignment problem. Core body temperature has to start dropping, melatonin has to arrive on time, and the arousal systems that keep you ruminating have to quiet down. Each trick below targets one of those levers, and each comes with a gadget that either helps or oversells it.</p><p>The clinical benchmark is worth stating first, because everything else here sits well below it. The American Academy of Sleep Medicine treats cognitive behavioral therapy for insomnia (<strong>CBT-I</strong>) as the standard of care, and an app version, <strong>Somryst</strong>, received <a href="https://aasm.org/digital-treatment-for-insomnia-receives-fda-clearance/">FDA authorization in 2020</a> after two randomized trials enrolling more than <strong>1,400 adults</strong>. I did not check its current availability. The five tricks are for ordinary sleep-onset trouble. If you have struggled for weeks, that is a clinician&#8217;s question, not a gadget question. They run from best supported to least.</p><h2>1. A warm bath or shower 1 to 2 hours before bed</h2><p>This is the best-evidenced item here, and it costs nothing. A <a href="https://doi.org/10.1016/j.smrv.2019.04.008">meta-analysis in </a><em><a href="https://doi.org/10.1016/j.smrv.2019.04.008">Sleep Medicine Reviews</a></em> screened <strong>5,322 candidate articles</strong>, kept <strong>17</strong>, and found that water-based passive heating at <strong>40 to 42.5 &#176;C</strong>, scheduled 1 to 2 hours before bedtime for as little as <strong>10 minutes</strong>, significantly shortened sleep onset latency. The University of Texas at Austin team that ran it <a href="https://cockrell.utexas.edu/?p=23504">reported an average speedup of about 10 minutes</a>.</p><p>The mechanism is counterintuitive. Warm water pulls blood out to the hands and feet, which dumps core heat, and core temperature already falls by roughly <strong>0.5 to 1 &#176;F</strong> about 90 minutes before habitual sleep. The bath amplifies a drop the body was about to make. That is also why timing matters: the lead author said a bath <a href="https://www.ksl.com/article/news/features/lifestyle/a-hot-bath-1-or-2-hours-before-bedtime-can-significantly-improve-your-sleep-researchers-say/46601029">15 minutes before bed was too soon</a> to get the same effect.</p><p>The gadget angle is still a prototype. The same group is <a href="https://cockrell.utexas.edu/?p=23504">working on a bed system</a> built on its patented Selective Thermal Stimulation technology. That is research-stage, and I found no cleared or commercial product. The included studies varied a lot in method, so treat the 10 minutes as an average, not a promise.</p><h2>2. Dim the lights after dinner</h2><p>Room light is a stronger signal than most people assume. In a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3047226/">study of 116 volunteers</a>, exposure to room light in the 8 hours before bed delayed melatonin onset in <strong>99%</strong> of individuals compared with dim light and shortened melatonin duration by about <strong>90 minutes</strong>. Work from Monash University found that <a href="https://www.monash.edu/turner-institute/news-and-events/latest-news/2019-articles/light-the-night-monash-research-finds-that-some-of-us-are-hypersensitive-to-evening-illumination">about 30 lux</a>, typical of a lit living room, suppressed melatonin by half at group level and delayed its onset by <strong>77 minutes</strong>. Sensitivity varied more than <strong>50-fold</strong> between people.</p><p>A small <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4053688/">home-lighting crossover study</a> of 8 healthy adults compared roughly <strong>64 lux</strong> with <strong>2.7 lux</strong> in the four hours before bed and found that home light alone altered circadian timing.</p><p>The caveat is about what was measured. These trials track <em>melatonin and clock timing</em>, not minutes to fall asleep, and I found no trial here with sleep onset latency as the primary outcome. The mechanism is strong and the direct payoff is less proven. The gadget is a dimmer switch, which is pleasingly unglamorous. Do you know how bright your living room is at 9 p.m.? Because the 50-fold spread means you may be one of the sensitive ones.</p><h2>3. Slow breathing at about six breaths a minute</h2><p>Slow paced breathing, around <strong>0.1 Hz</strong>, shifts autonomic balance toward vagal activity. A <a href="https://hub.tmu.edu.tw/en/publications/efficacy-of-paced-breathing-for-insomnia-enhances-vagal-activity-/">Psychophysiology study</a> had insomniacs practice 20 minutes of it before sleep. Total heart rate variability power rose, and sleep onset latency, awakenings and awake time fell. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7198497">Scientific Reports pilot</a> in young adults, a randomized crossover with polysomnography, also found a single 20-minute session before bed reduced sleep onset latency.</p><p>Both trials are small. The Psychophysiology work used <strong>14 insomniacs</strong>, and the pilot said outright that research here is sparse. Treat this as a plausible, low-risk habit.</p><p>The gadget story is humbling. A <strong>Somnox sleep robot</strong> simulates slow breathing against your chest. A 2023 trial in the <em>Journal of Sleep Research</em>, summarized by <a href="https://pubmed.ncbi.nlm.nih.gov/36285420/">a mattress retailer&#8217;s review</a> (I have not read the paper itself), randomized <strong>44 adults</strong> with insomnia to the robot or a waitlist for three weeks and reportedly found it ineffective at group level. The physiology holds up. A hardware device delivering it is not yet shown to add anything over a metronome app.</p><h2>4. Cognitive shuffling</h2><p><strong>Cognitive shuffling</strong>, formally <em>serial diverse imagining</em>, was developed by Simon Fraser University&#8217;s Luc Beaudoin. The idea is that worry, planning and rumination keep the executive system engaged, while good sleepers drift through loose, dream-like imagery. You pick a random word, imagine items beginning with each letter, and switch to an unrelated target <a href="https://www.canberratimes.com.au/story/8995447/can-cognitive-shuffling-help-you-sleep-two-experts-explain/">every 5 to 15 seconds</a>, without trying to connect them.</p><p>The evidence is preliminary. A <a href="https://sleepreviewmag.com/sleep-health/parameters/quality/need-better-sleep-consider-cognitive-shuffle/">conference presentation at SLEEP 2016</a> tested <strong>154 university students</strong> with excessive pre-sleep cognitive arousal. The imagery task matched a 15-minute structured problem-solving exercise at reducing pre-sleep arousal, sleep effort and poor sleep quality, with the advantage that it can be done in bed. Monash sleep researchers say the literature contains <a href="https://www.canberratimes.com.au/story/8995447/can-cognitive-shuffling-help-you-sleep-two-experts-explain/">only a small number of studies</a> and that more work is needed. Note the outcomes: arousal and effort, not a stopwatch.</p><p>The supporting gadget is Beaudoin&#8217;s own <strong>mySleepButton</strong> app, a consumer app with no independent trial that I could find. The honest takeaway is that the technique costs nothing to test. Try it for a week and see whether it shortens your <em>own</em> wait.</p><h2>5. Sound, from pink noise to closed-loop headbands</h2><p>Plain noise is the cheap end. A <a href="https://www.em-consulte.com/article/1421191/article/noise-as-a-sleep-aid-a-systematic-review">Sleep Medicine Reviews systematic review</a> of <strong>38 studies</strong> rated the evidence for continuous noise as a sleep aid as very low quality. A <em><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9163611/">Journal of Clinical Sleep Medicine</a></em><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9163611/"> review</a> of 34 studies with <strong>1,103 participants</strong> found positive results in 9 of 11 pink-noise studies but only 6 of 18 white-noise studies. Those studies are small and heterogeneous, so I would not buy anything on that basis.</p><p>The high-tech end is <strong>closed-loop acoustic stimulation</strong>. Alpha oscillations are elevated in insomnia, so <strong>Elemind</strong> built an EEG headband that times bone-conduction sound pulses to the phase of your alpha rhythm and <a href="https://bcs.mit.edu/news/startup-helps-people-fall-asleep-aligning-audio-signals-brainwaves">tapers the audio once it detects sleep</a>. A <a href="https://medrxiv.org/content/10.1101/2024.01.10.24301120.full.pdf">randomized crossover preprint</a> (NCT05743114) enrolled adults with EEG-verified onset latencies over 30 minutes. With <strong>21 participants analyzed</strong>, weekly average latency fell by <strong>10.5 minutes (29.3%)</strong>, p = 0.0019. The authors are Elemind employees and the company funded the work. Marketing for the product <a href="https://businesswire.com/news/home/20240604568537/en/Elemind-Launches-First-of-its-Kind-Sleep-On-Demand-Headband-Giving-Control-to-Millions-Struggling-with-Sleep">cites 76% of participants and a 48% average reduction</a>. That is a different, larger number, and I could not trace it to a single analysis.</p><p><strong>Somnee</strong> takes another route: 15 minutes of transcranial alternating current stimulation (tACS) before bed. Its <a href="https://hitconsultant.net/?p=66185">launch announcement</a> cites a 1,500-night home pilot in which time to fall asleep was cut in half. That is company data, not an independent trial. Both products are sold as wellness devices, not medical treatments. If you&#8217;re following this area of neurotech professionally, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> gives you the structured intelligence feed to go deeper than any single article can.</p><p>Tonight&#8217;s experiment costs nothing. Take the bath 90 minutes before bed, dim the lights, and note how long you lie awake. If a headband still tempts you, which result would you demand first: an independent, sham-controlled trial, or a larger sample than 21?</p>]]></content:encoded></item><item><title><![CDATA[5 Tech-Assisted Ways to Beat Afternoon Brain Fog]]></title><description><![CDATA[Light, caffeine naps, paced breathing, ear stimulation and brain stimulation headsets all promise a 3 p.m. fix, and the evidence behind each differs sharply.]]></description><link>https://www.neurotechmag.com/p/5-tech-assisted-ways-to-beat-afternoon</link><guid isPermaLink="false">https://www.neurotechmag.com/p/5-tech-assisted-ways-to-beat-afternoon</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Thu, 19 Nov 2026 17:41:28 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!fYF7!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!fYF7!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!fYF7!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!fYF7!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!fYF7!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!fYF7!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!fYF7!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/a76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2541680,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/223059086?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!fYF7!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!fYF7!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!fYF7!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!fYF7!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa76175a7-a7ef-4257-aaef-cd823246922f_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>The 2 p.m. wall is only partly your lunch. A <a href="https://www.ndph.ox.ac.uk/study-with-us/student-blog/201cpost-lunch-dip201d-and-napping">University of Oxford student explainer</a> walks through Borbely&#8217;s <strong>two-process model</strong>: sleep pressure keeps climbing through the day, and the circadian alerting drive that should counter it <strong>dips in the early afternoon</strong>. That gap can open even without a lunch break. Eating makes it worse, because the <a href="https://blog.donders.ru.nl/why-we-get-tired-after-having-a-meal/?lang=en">Donders Institute notes</a> that larger meals and a poor night of sleep deepen the dip.</p><p>So the target is <em>sleep pressure and circadian timing</em>, not willpower. Every technology below tries to hit one of those two levers, and they sit at very different points on the evidence ladder. I have ordered them from best supported to least. One caveat first: this is about the ordinary dip in healthy people. Fog that persists for weeks is a medical question, not a gadget question.</p><h2>1. A bright task lamp, if you sleep badly</h2><p>The best-controlled result is also the least glamorous. In a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10424162">2023 study in </a><em><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10424162">Sleep</a></em> (NCT04745312), <strong>16 healthy young adults</strong> spent three days in an inpatient unit and worked two simulated <strong>8-hour workdays</strong> under sleep restriction. Room light was dim, about <strong>30 melanopic EDI lux</strong>. Adding a single <strong>high-melanopic task lamp</strong> on the work surface improved alertness and several domains of cognition. Melanopic light is weighted toward melanopsin, the pigment in the eye cells that feed the body clock.</p><p>A separate <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229615/">simulated-office study</a> found that repeated <strong>bright white light pulses</strong> from 7:30 a.m. improved attention, and noted that earlier reviews describe a small but significant effect on attention.</p><p>The counterweight matters. A <a href="https://publica.fraunhofer.de/handle/publica/458742">Fraunhofer test of &#8220;virtual sky&#8221; lighting</a> on <strong>18 healthy, well-rested young men</strong> over 8 hours found no significant effect on alertness or cognitive performance. My reading: light helps when your baseline is dim or your sleep is short, and does little for a rested person already under decent lighting. This is lab and simulated-office evidence in small samples, but the hardware is ordinary lighting with no regulatory friction.</p><p>Do you know your desk&#8217;s actual lux level? Most people have never measured it, and that is the cheapest experiment on this list.</p><h2>2. A timed coffee nap</h2><p>The rationale is tidy. Caffeine takes roughly 20 minutes to act, so you drink it, nap, and wake as it lands. The <a href="https://www.sleepfoundation.org/napping/coffee-nap">Sleep Foundation&#8217;s guidance</a> puts the dose near <strong>200 mg</strong> and the nap at about <strong>20 minutes</strong>, taken after lunch and not close to bedtime. Longer naps risk <strong>sleep inertia</strong>, the grogginess the Oxford explainer warns about, which is why short naps are the standard advice.</p><p>The evidence is thinner than the advice. A <a href="https://swov.nl/en/publicatie/falling-asleep-wheel">driving-simulator study</a> tested caffeine (150 mg) and a nap of under 15 minutes as <em>separate</em> treatments between 14:00 and 16:30. Both cut driving errors, subjective sleepiness and drowsy EEG activity for about an hour. The caffeine effect was consistent across subjects, while the nap effect depended on whether people could actually fall asleep. Claims that the <em>combination</em> beats either alone rest on smaller work, including a Japanese study of <a href="https://scrippsnews.com/stories/coffee-then-napping-the-key-to-alertness">just 10 participants</a>, and the Oxford explainer calls systematic reviews of napping inconclusive.</p><p>The tech angle is where I would be careful. A phone timer does the job. A sleep headband could in principle confirm that you dozed, but the <strong>Muse-S</strong> was validated overnight, with a <a href="https://espace2.etsmtl.ca/id/eprint/33349/">Cohen&#8217;s kappa of 0.76 against polysomnography in 56 adults</a>. I found no validation for 20-minute daytime naps. Treat headband-confirmed napping as an untested extrapolation.</p><h2>3. Paced breathing with HRV feedback, and not EEG neurofeedback</h2><p><strong>Heart rate variability biofeedback</strong> teaches you to breathe near your resonant frequency, around <strong>six breaths per minute</strong>, while a sensor shows heart rhythm in real time. In an <a href="https://irep.iium.edu.my/59941/">industrial study of electronics-manufacturing operators</a>, an experimental group did <strong>five weekly sessions</strong> of 30 to 50 minutes. Cognitive performance rose alongside <strong>HRV</strong>, with slower respiration during sessions. It is a workplace pilot, not proof that it will clear your 3 p.m. fog, but it is low risk and uses sensors many people already wear.</p><p>EEG neurofeedback looks like the sophisticated cousin, and it has not earned that status for this job. A <a href="https://doi.org/10.1371/journal.pone.0211668">sham-controlled study of 33 participants</a> used a consumer <strong>Emotiv Epoc</strong> headset over four consecutive days of upper-alpha training. It found no effect on digit-span performance, and scores rose in <em>both</em> groups, which is just what practice does. Peak consumer-grade hardware did not turn alpha training into a focus boost here.</p><h2>4. Ear stimulation, which is a research story, not a shopping story</h2><p><strong>Transcutaneous auricular vagus nerve stimulation</strong> (taVNS) puts a small current on the ear, targeting a branch of the vagus nerve. Three research contexts matter, and they should not be blended.</p><p>The military one: a <a href="https://doi.org/10.1186/s41235-026-00730-0">2026 study in </a><em><a href="https://doi.org/10.1186/s41235-026-00730-0">Cognitive Research</a></em> tested taVNS during a military exercise with acute sleep deprivation. It reported potential to support vigilance in monotonous tasks such as radar monitoring. The healthy-volunteer one: a <a href="https://www.ftrdergisi.com/abstract.php?id=4458">2023 Turkish study</a> found a benefit for visual memory but no apparent effect on fatigue. The medical one: the <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13471458/">ReVita trial protocol</a> (DRKS00038292) is a sham-controlled test of home taVNS in patients with <strong>pathological fatigue</strong>. That is a protocol, not a result, and those patients are not people with a 3 p.m. slump.</p><p>Every paper, funding round, and trial update we report on ends up summarized and searchable in <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a>, which is useful here because taVNS trials are multiplying faster than any single article can track. For context on what clearance looks like, <a href="https://neurotechreports.com/?p=8894">Neurotech Reports</a> describes <strong>Nerivio</strong>, an FDA-cleared wearable for migraine. I found no cleared device for afternoon alertness. Stage: research, with medical use in trials.</p><h2>5. Brain stimulation headsets, the least ready of the five</h2><p>Two technologies get marketed for focus. <strong>tDCS</strong> runs a weak current through the scalp. A <a href="https://bps.org.uk/research-digest/trouble-tdcs-electrical-brain-stimulation-may-not-work-after-all">Research Digest summary of Horvath and colleagues</a> concluded that single-session tDCS has no reliable cognitive effect in healthy adults. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5020062">pre-registered study</a> argued that typical tDCS samples are underpowered, citing average statistical power under <strong>50%</strong>. A <a href="https://repository.upenn.edu/neuroethics_pubs/153/">working-memory meta-analysis</a> found that the left-prefrontal effect vanished after publication-bias correction, with a small gain only when stimulation was paired with training.</p><p><strong>Transcranial photobiomodulation</strong> (tPBM) shines near-infrared light on the forehead. A <a href="https://doi.org/10.1002/JOCB.70112">2026 double-blind study</a> of <strong>56 healthy participants</strong> used 810 nm light pulsed at 40 Hz over both prefrontal cortices for 20 minutes. It called tPBM a promising tool for convergent thinking and Stroop performance. The earlier <a href="https://pubmed.ncbi.nlm.nih.gov/23200785/">2013 laser study</a> was an early controlled trial, and a <strong><a href="https://clinicaltrials.gov/study/NCT05802680">500-person</a></strong><a href="https://clinicaltrials.gov/study/NCT05802680"> attention trial at the University of Texas at Austin</a> is listed as recruiting. None of it addresses afternoon fatigue directly.</p><p>Marketing runs ahead anyway. In May 2026, <a href="https://pulse2.com/sychedelic-3-5-million-funding/amp/">Sychedelic announced a seed round</a> for headphones that combine tDCS, binaural audio and HRV feedback. The company says the product helps users relax, focus or sleep in as little as 20 minutes. That is a company claim, not a trial result.</p><p>If you are building in this space, the opening is an honest trial on the afternoon dip itself, with a sham arm and enough participants to detect a modest effect. If you are a user, start with the lamp and the nap, log your 2 p.m. sleepiness for a week, and ask which of the other three has a trial you could actually read.</p>]]></content:encoded></item><item><title><![CDATA[What Is Your Brain Actually Doing? 5 Things an EEG Headband Can (and Can't) Tell You]]></title><description><![CDATA[Consumer EEG is good at a few narrow jobs and unproven at the ones marketing leans on, so here is where each claim sits on the evidence ladder.]]></description><link>https://www.neurotechmag.com/p/what-is-your-brain-actually-doing</link><guid isPermaLink="false">https://www.neurotechmag.com/p/what-is-your-brain-actually-doing</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Wed, 18 Nov 2026 17:40:32 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!SlI4!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!SlI4!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!SlI4!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!SlI4!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!SlI4!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!SlI4!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!SlI4!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2658508,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/223059030?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!SlI4!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!SlI4!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!SlI4!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!SlI4!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1c84475c-7aca-4de5-84ce-136ccf18ad54_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>A consumer EEG headband listens to your brain through a keyhole. The <strong>Muse</strong> line, for example, records <strong>four dry-electrode channels</strong> (AF7, AF8, TP9, TP10) at <strong>256 Hz</strong>, according to the <a href="https://github.com/DominiqueMakowski/OpenMuse">open-source decoder for the Muse S Athena</a>, which also adds an fNIRS sensor for frontal blood oxygenation. A routine hospital EEG, by contrast, uses a 19-channel montage. Four channels can still say real things about <em>global</em> brain states. They cannot say much about anything that depends on <em>where</em> in the cortex activity happens.</p><p>That gap explains the whole category. EEG is the dominant technology in consumer neurotech, used by <a href="https://cfg.eu/press-release-brain-sensing-wearables/">nearly 65% of consumer firms</a> in one market mapping, largely because it is portable, safe and sidesteps medical device rules. The devices are <strong>on the market</strong> as wellness products. Whether the scores they output mean what the app says is a separate question, and the answer changes sharply from one claim to the next. Five of the most common claims follow, ordered from best supported to least.</p><h2>1. Whether you are asleep, and roughly how deep</h2><p>This is the strongest use case, and the evidence is real. In a <a href="https://espace2.etsmtl.ca/id/eprint/33349/">2026 </a><em><a href="https://espace2.etsmtl.ca/id/eprint/33349/">SLEEP Advances</a></em><a href="https://espace2.etsmtl.ca/id/eprint/33349/"> study</a>, <strong>56 adults</strong> slept one night in a lab wearing a <strong>Muse-S</strong> while level 1 polysomnography ran alongside. The device&#8217;s automated staging reached <strong>Cohen&#8217;s kappa of 0.76</strong>, which counts as substantial agreement. The Muse-S ran slightly long on deep sleep (<strong>+15 minutes of NREM3</strong> on average).</p><p>The reported <strong>88% to 96% per-stage accuracy</strong> looks better than it is. Per-stage figures tend to run higher than four- or five-class agreement, so kappa is the number to watch. The authors themselves call for validation in more diverse populations.</p><p>The <strong>Dreem headband</strong> (five dry electrodes, accelerometer, pulse oximeter) has a longer paper trail. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7751170">validation study against polysomnography</a>, registered as NCT03725943, found the algorithm reached <strong>83.5% overall accuracy</strong> against <strong>86.4%</strong> for the five human experts it was compared with. That is within expert-to-expert disagreement. REM detection was the weak spot in a <a href="https://medrxiv.org/content/early/2024/12/18/2024.12.18.24319240.full">preprint on 62 older adults</a>, 12 of whom had Alzheimer&#8217;s.</p><p>Home use is the harder test. A <a href="https://www.medrxiv.org/content/10.64898/2026.06.01.26354591v1.full.pdf">June 2026 preprint</a> on 100 home sleepers wearing the <strong>Zmax</strong> (F7-Fpz and F8-Fpz at 256 Hz) found agreement drop to <strong>kappa 0.450</strong> with the better of two algorithms, <strong>even after excluding recordings with bad signal</strong>. Both algorithms confused N2 and N3 sleep, in opposite directions. <em>Not peer reviewed yet</em>, but it matches what you would expect when a headband slides around at 3 a.m.</p><p>If you wear one, do you trust the stage chart or just the total sleep time? The evidence favors the second.</p><h2>2. Broad rhythms, like alpha rising when you close your eyes</h2><p>Spectral power is what a few frontal channels do reasonably well. Closing your eyes and relaxing raises <strong>alpha-band power</strong>, and cheap hardware sees it. A <a href="https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2017.00109/full">2017 </a><em><a href="https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2017.00109/full">Frontiers in Neuroscience</a></em><a href="https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2017.00109/full"> study</a> recorded <strong>60 participants</strong> on a Muse during an oddball task and a reward-learning task, and showed it can recover <strong>event-related potentials</strong> at all. Later work <a href="https://www.biorxiv.org/content/biorxiv/early/2021/11/04/2021.11.02.466989.full.pdf">compared Muse spectra against a 64-channel BioSemi system</a> and tested frontal alpha asymmetry and individual alpha frequency.</p><p>The catch is signal quality across devices. A <a href="https://doi.org/10.3389/fnins.2024.1326139">2024 comparison of dry devices against gel electrodes</a> found distinct quality profiles and reported that the <strong>Muse had several limitations in signal quality</strong>. Two headbands are not interchangeable instruments.</p><p>Whether frontal alpha asymmetry means anything about <em>mood</em> is a different and contested claim. The headband can compute the number. It cannot tell you what the number means.</p><h2>3. Whether you are focused</h2><p>Here the evidence thins out. A <a href="https://doi.org/10.3389/fninf.2020.553352">systematic review of consumer drowsiness detection</a> covered <strong>46 relevant studies</strong>. About 27 reported an accuracy score, and the lowest was <strong>31% for the NeuroSky MindWave</strong>. The second lowest was <strong>79.4%</strong> for an OpenBCI study. That spread says more about study design than about brains.</p><p>Then there is <strong>artifact</strong>. Muscle activity sits mainly above 20 Hz, <a href="https://www.emotiv.com/neuroscience/eeg-artifacts">in the beta and gamma bands</a> where many cognitive measures live. A furrowed brow or clenched jaw is muscle, and muscle is loud. A <a href="https://repository.essex.ac.uk/42395/">dry-EEG benchmark from the University of Essex</a> found dry systems held up in moderate-noise scenarios but showed <strong>more muscle artifact in dynamic conditions</strong>, notably in frontal and temporal regions. Those are exactly the regions a headband covers.</p><p>Neurable&#8217;s <strong>MW75 Neuro</strong> headphones launched September 2024 at <strong>$699</strong>, and the <a href="https://www.businesswire.com/news/home/20240924893354/en/Neurable-Inc.-Launches-First-Smart-Brain-Computer-Interface-Enabled-Headphones-for-Consumer-Market">company&#8217;s launch release</a> describes focus tracking and brainwave data review. Neurable&#8217;s own product page cites an average <strong>33% increase in focus time</strong>, which is a company figure, not an independent trial. One <a href="https://bgr.com/reviews/master-dynamic-mw75-neuro-headphones-that-read-your-mind/">hands-on review</a> found the tracked metrics not especially useful. A focus score is best read as a <em>trend line for you</em>, not a measurement.</p><h2>4. Whether you are stressed, anxious or calm</h2><p>This is where I would stop trusting the app. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6629579">neuroethics analysis in </a><em><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6629579">PMC</a></em> noted that many consumer EEG devices claim to read emotional state as stressed, meditative or focused, yet <strong>these claims had not been independently validated</strong>. That paper dates from 2019. In this research pass I found no independent validation that closes the gap, though I would be glad to be pointed to one.</p><p>The authors also flagged a specific harm worth repeating. A false &#8220;stressed&#8221; reading can make a person <em>more</em> stressed. A wrong sleep stage costs you nothing. A wrong anxiety score changes how you feel about your day.</p><p>The physics does not help. Emotion draws on deep structures, including the amygdala, that scalp EEG sees only indirectly through a few forehead and mastoid contacts. Other signals that ride along (heart rate, muscle tone, movement) may carry more of the stress signal than the brain channels do. Ask the vendor which one the model leans on.</p><h2>5. Anything medical</h2><p>A headband cannot diagnose epilepsy, ADHD or depression, and wellness products are legally barred from implying they do. The regulatory logic is that <a href="https://cfg.eu/introducing-neurotech-between-wellness-and-medicine/">intended purpose, not the technology, decides whether a device is medical</a>. A University of British Columbia team <a href="https://www2.computerworld.com.au/article/662040/wearable-brain-devices-sold-questionable-claims/">reviewed consumer brain devices</a> and found that only one had FDA approval while nine claimed medical benefits.</p><p>Clinical wearable EEG exists, and it is a different class of product. According to <a href="https://neurotechreports.com/?p=8894">Neurotech Reports</a>, Epitel closed a Series B in September 2026 to expand its <strong>REMI</strong> wireless system, which pairs weeks-long at-home EEG with AI seizure detection and carries <strong>five FDA 510(k) clearances</strong>. That product answers a clinical question under regulatory scrutiny. Your sleep headband does not.</p><p>Developments like this rarely happen in isolation, and <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> tracks the research, funding, and trials that surround them. For now, the practical rule is simple: if marketing promises a medical outcome, ask for a clearance number. If there is none, treat the output as a diary, not a diagnosis.</p><p>So the next time your headband hands you a score, ask the question this article keeps circling: is this a reading of your brain, or a guess drawn from a few noisy forehead channels?</p>]]></content:encoded></item><item><title><![CDATA[6 Ways to Read Your Sleep Tracker Without Panicking Over Bad Scores]]></title><description><![CDATA[A low number on your wrist is a weak signal, and six habits keep it from becoming a bad morning or a worse night.]]></description><link>https://www.neurotechmag.com/p/6-ways-to-read-your-sleep-tracker</link><guid isPermaLink="false">https://www.neurotechmag.com/p/6-ways-to-read-your-sleep-tracker</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Fri, 13 Nov 2026 15:01:32 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!5vGQ!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!5vGQ!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!5vGQ!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!5vGQ!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!5vGQ!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!5vGQ!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!5vGQ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2199865,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/222503339?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!5vGQ!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!5vGQ!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!5vGQ!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!5vGQ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17bd4a24-ce22-4cd4-9276-65d2186b90f9_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Picture the 61. You were in bed for eight hours, you feel fine, and the app still calls the night &#8220;fair.&#8221; The number can ruin a morning before the coffee is done. It can also start a loop where worry about sleep costs you sleep. This guide is about <strong>consumer wellness</strong> data from rings, bands and watches. It is not about diagnosis, and the difference matters more than any score.</p><h2>Know what the score is made of</h2><h3>1. Treat the headline score as a house recipe</h3><p>Oura Readiness, WHOOP Recovery and Garmin Body Battery are <strong>composite scores</strong>, blends of sleep, heart rate, HRV and other signals under proprietary weights. One <a href="https://www.gneta.app/blog/recovery-scores-compared-garmin-whoop-oura">roundup of Doherty and colleagues&#8217; catalog</a> of 14 composite scores across 10 manufacturers found no published head-to-head validation of those three, and none of the companies publishes its formula. So the same night can produce <em>different</em> numbers on different devices, and each can be &#8220;right&#8221; by its own logic. Use your own score as a trend line against your own baseline. Do not read it as a grade.</p><h3>2. Trust duration and timing, discount the stage breakdown</h3><p>Validation work backs this split. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9412437">lab comparison of six wearables against polysomnography</a> found <strong>86% to 89%</strong> sleep/wake agreement and judged all six valid for the timing and duration of sleep. Agreement on specific sleep stages fell to <strong>50% to 65%</strong>. A 2026 systematic review reported by <a href="https://www.sciencealert.com/?p=217255">ScienceAlert</a> concluded that wearables may give reasonable feedback on duration and regularity in healthy people. The same review&#8217;s figures, summarized by <a href="https://xenospectrum.com/en/sleep-tracker-subjective-quality-gap-review/">XenoSpectrum</a>, show devices tend to overestimate sleep efficiency and undercount wakeful time after sleep onset. In other words, they often count quiet wakefulness as sleep. A &#8220;low deep sleep&#8221; alert deserves a shrug.</p><h2>Zoom out from a single night</h2><h3>3. Judge a two-week window, and discount first nights</h3><p>Healthy sleepers are noisy. Pooled data from eight datasets covering <a href="https://experts.arizona.edu/en/publications/how-much-does-sleep-vary-from-night-to-night-a-quantitative-summa/">2,404 healthy sleepers and 26,121 days</a> put the night-to-night standard deviation of sleep duration at roughly <strong>67 to 86 minutes</strong>, depending on the method. If you average 7 hours 50 minutes, a 6 hour 40 minute night sits inside ordinary variation. New environments add a predictable dent: people sleep about <a href="https://www.clickorlando.com/health/2026/08/11/have-trouble-sleeping-in-a-new-place-most-do-because-of-the-first-night-effect/">20 to 30 minutes less in an unfamiliar place</a>, and the effect fades after the first night. Your tracker will log that faithfully. Read a rolling 14-day average, and mark hotel nights and late flights as exceptions.</p><h3>4. Watch regularity as closely as hours</h3><p>If you want one number to improve, consider <strong>sleep regularity</strong>, the day-to-day consistency of sleep and wake times. In a UK Biobank analysis of <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10782501">60,977 people wearing wrist accelerometers for a week</a>, regularity predicted all-cause mortality more strongly than duration did. The top four regularity quintiles carried a 20% to 48% lower risk than the least regular one. That is an <em>observational</em> result from one week of data, so it shows association, not proof that tightening your schedule extends your life. It does give you an actionable, device-friendly target: a consistent wake time costs nothing and shows up cleanly in your timing data.</p><h2>Check the number against how you feel</h2><h3>5. Pair the score with a one-line morning rating, and set a tracking limit</h3><p>Device data and your experience of sleep overlap less than you might expect. In that 2026 review, device metrics explained only <strong>2.5% to 16.2%</strong> of the variation in perceived sleep quality, and agreement with subjective ratings was 82.4% in good sleepers but 39.4% in people with insomnia. The reverse failure is the one to watch. Clinicians described <strong>orthosomnia</strong> in a <a href="https://entm.ag/djf">2017 case report</a>: patients spent extra time in bed chasing the tracker&#8217;s reported duration, which may have worsened their insomnia. A <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592250/">2024 cross-sectional study of 523 adults</a> put prevalence at 3% to 14% depending on the definition, with higher insomnia scores in those affected. A nationally representative <a href="https://academic.oup.com/sleep/article/49/Supplement_1/A246/8674102">2026 conference abstract</a> found 30.9% of trackers screened positive for orthosomnia risk on an adapted anxiety measure. That is an abstract, so treat it as preliminary.</p><p>Try this tomorrow: write a 1 to 5 rating of how rested you feel <em>before</em> you open the app, then compare. If the tracker says &#8220;bad&#8221; and you feel fine, treat it as noise. If tracking itself makes you anxious, take a break. Sleep neurologist Chris Winter, quoted by <a href="https://www.webmd.com/sleep-disorders/news/20241014/cm/fixation-perfect-nights-sleep-becomes-harmful">WebMD</a>, suggested setting the device aside until sleep settles. How far apart did your two numbers land?</p><h2>Know when a score should send you to a clinician</h2><h3>6. Treat persistent symptoms and apnea flags as medical questions</h3><p>The American Academy of Sleep Medicine&#8217;s 2018 <a href="https://www.aasm.org/advocacy/position-statements/consumer-sleep-technology/">position statement</a> said consumer sleep devices could not be used for diagnosis or treatment because of limited validation and no FDA clearance. One part of that has moved. Samsung received FDA De Novo authorization in February 2024 for a <a href="https://www.medtechdive.com/news/samsung-fda-watch-sleep-apnea/707335/">sleep apnea risk feature</a>, explicitly not intended to replace diagnosis, and Apple followed with a 510(k) clearance that September. <a href="https://engadget.com/2200959/can-smartwatch-detect-sleep-apnea">Engadget</a> reported that Fitbit and WHOOP have no FDA-cleared respiratory feature in the same category. Your nightly score, however, has no such authorization. If you&#8217;re following this area of neurotech professionally, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> gives you the structured intelligence feed to go deeper than any single article can.</p><p>Three situations justify a call, whatever the app says:</p><ul><li><p><strong>Persistent daytime sleepiness or fatigue.</strong> The AASM says that warrants a conversation with a licensed provider regardless of what a wearable reports.</p></li><li><p><strong>A sleep apnea notification</strong> from a supported Apple or Samsung watch. <a href="https://www.aarp.org/personal-technology/sleep-apnea-smartwatch/">AARP&#8217;s guidance</a> notes these are meant for adults without a prior diagnosis, with a doctor visit as the next step.</p></li><li><p><strong>An ongoing sleep problem</strong> that has lasted weeks, even when your scores look fine.</p></li></ul><p>A tracker is a decent logbook for duration and timing and a poor judge of how well you slept. If you could keep only one habit from this list, would you pick the two-week average, the fixed wake time or the morning rating?</p>]]></content:encoded></item><item><title><![CDATA[How to Use Your Wearable's Data to Find Your Best 3 Focus Hours]]></title><description><![CDATA[Your ring or watch cannot measure focus, but two weeks of its sleep and heart data can show you when yours holds up.]]></description><link>https://www.neurotechmag.com/p/how-to-use-your-wearables-data-to</link><guid isPermaLink="false">https://www.neurotechmag.com/p/how-to-use-your-wearables-data-to</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Thu, 12 Nov 2026 14:58:29 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!Y5tB!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!Y5tB!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!Y5tB!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!Y5tB!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!Y5tB!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!Y5tB!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!Y5tB!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2268583,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/222503015?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!Y5tB!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!Y5tB!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!Y5tB!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!Y5tB!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F196d9d11-bdb8-4090-a339-9189311836e7_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>No consumer wearable on the market reads attention directly. A ring, band or watch logs <strong>sleep timing</strong>, <strong>heart rate</strong>, <strong>pulse-derived heart rate variability (HRV)</strong>, skin temperature and movement. Whether those signals predict a good afternoon of deep work is a separate question, and it is <em>your</em> question to answer with your own numbers. This guide treats the wearable as a lab notebook, not an oracle. Everything here is consumer wellness territory. None of it is diagnosis, and none of it replaces a clinician if your sleep data looks alarming.</p><h2>What your wearable can and cannot tell you</h2><p>Start with trust levels, because they differ a lot by metric. In a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9412437">laboratory validation of six wearables against polysomnography</a>, sleep/wake agreement ranged from <strong>86% to 89%</strong> across Apple Watch, Garmin, Polar, Oura, WHOOP and Somfit, and the authors judged all six valid for the <strong>timing and duration of sleep</strong>. Stage-level agreement was far worse, <strong>50% to 65%</strong>. A later <a href="https://pmc.ncbi.nlm.nih.gov/articles/pmc11511193">single-night inpatient study of 35 adults</a> compared Oura, Fitbit and Apple Watch the same way. Oura&#8217;s own summary of that paper said the Apple Watch overestimated light and deep sleep by roughly 45 and 43 minutes. That is a company reading of the data, so weigh it accordingly.</p><p>HRV needs more caution. A wrist optical sensor measures pulse intervals, not the heart&#8217;s electrical signal. One validation of the Garmin Elevate v4 sensor found it <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13709044/">reliable for within-subject trends but not accurate enough</a> to replace ECG-derived HRV for resting autonomic evaluation in an individual. Another group concluded that <a href="https://research.vu.nl/en/publications/quality-in-question-assessing-the-accuracy-of-four-heart-rate-wea/">PPG devices may pose validity concerns</a> for HRV outside resting conditions.</p><p>So use three rules. Trust <strong>sleep duration and timing</strong>. Treat <strong>HRV as a trend against your own baseline</strong>, read overnight or first thing in the morning, never mid-meeting. Ignore <em>sleep stage</em> breakdowns for scheduling decisions.</p><h2>The signals that plausibly map to attention</h2><p>Sleep is the best-supported lever. In lab studies, vigilance is the cognitive function that sleep loss damages most reliably, measured by lapses on the psychomotor vigilance task. One study of <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8455079">49 people after a night of total sleep deprivation</a> found slower reactions and more lapses, plus worse inhibition control. A crossover trial reported that <a href="https://serval.unil.ch/notice/serval:BIB_105292044ED2">six nights of extended sleep</a> improved baseline vigilance and limited lapses during later sleep deprivation. Your wearable&#8217;s sleep duration number is therefore the input most worth logging.</p><p>HRV is the weaker candidate. A <a href="https://frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.00710/full">systematic review of 20 studies and 19,431 participants</a> linked higher parasympathetic activity to better cognitive performance, with the authors flagging limited evidence outside executive function. In a lab study of 56 people, <a href="https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2023.1292983/pdf">higher resting vagally mediated HRV went with better attentional control</a>. Those are population associations. Whether <em>your</em> low-HRV morning means a bad focus afternoon is exactly what the experiment below tests.</p><p>Time of day is the third input. Cognitive performance varies across the day and depends on chronotype. A well-cited review calls this the <a href="https://orbi.uliege.be/handle/2268/4666">synchrony effect</a>: performance is better when the task lines up with your circadian arousal peak. The APA&#8217;s summary notes that <a href="https://www.apa.org/monitor/2018/06/good-timing.html">off-peak, inhibition wavers and tuning out distraction gets harder</a>. The effect is not universal, though. A 2026 oddball-task study found <a href="https://orbi.uliege.be/bitstream/2268/347408/1/Scmidt%202026%20JSR.pdf">no behavioural effect of chronotype or time of day</a> in its young sample, even while brain activity differed. A flat personal curve is a legitimate result.</p><h2>Run a two-week experiment</h2><p>You need two things the wearable lacks: a focus outcome and a consistent routine. Here is a protocol that fits a normal workday:</p><ul><li><p><strong>Days 1 to 3, baseline only.</strong> Wear the device nightly. Note your average sleep duration and your sleep midpoint (halfway between falling asleep and waking), a rough proxy for chronotype.</p></li><li><p><strong>Every day, rate focus.</strong> At fixed times, say every two hours, score the <em>previous</em> block from 1 to 5. Ask one question: could I hold one hard task without switching?</p></li><li><p><strong>Add one objective check.</strong> Do a short reaction-time test at the start of two or three blocks. Research versions of that test run about 10 minutes, so treat a shortened one as rough.</p></li><li><p><strong>Log inputs, not just outputs.</strong> Record last caffeine time, last meal, a meeting-heavy day, and hard workouts. Add the morning&#8217;s sleep duration and HRV relative to your 14-day average.</p></li><li><p><strong>Days 14 and after, analyze.</strong> Average focus by hour block. Pick your top three hours. Then split days by prior-night sleep (above or below your median) and compare.</p></li></ul><p>Fourteen days gives you about fourteen observations per time slot, which is noisy. Treat the first result as a hypothesis. Schedule your hardest work in the winning window for another two weeks and see whether it holds. What is the one confound you suspect is hiding in your own routine?</p><h2>The 90-minute question and EEG headphones</h2><p>Many productivity guides say you focus in 90-minute cycles. The idea comes from Nathaniel Kleitman&#8217;s basic rest-activity cycle. The <a href="https://en.wikipedia.org/wiki/Basic_rest%E2%80%93activity_cycle">evidence picture is mixed</a>: a meta-analysis cited there found strong evidence for daytime ultradian cycles in things like focus and reaction time, but through different mechanisms than the nocturnal sleep cycles, and most of the research centers on night. Use it as a testable guess. Look at your hourly ratings and see whether focus sags 80 to 120 minutes into a block.</p><p>Consumer EEG goes one step closer to the brain, and it is a different class of product. Neurable&#8217;s headphones put <a href="https://spectrum.ieee.org/eeg-headphones-neurable-one">12 EEG channels in the ear pads</a> and estimate a focus score. The company&#8217;s validation preprint described its own work as <a href="https://www.biorxiv.org/content/10.1101/2021.06.21.448991.full.pdf">preliminary, in a limited number of participants</a>, and a separate company study covers <a href="https://www.neurable.com/research/detecting-focus-states-in-office-environment-with-neurable-eeg-headset">43 participants over 114 hours of work sessions</a>. <em>IEEE Spectrum</em> quoted a researcher who warned that overpromising could trigger another hype cycle, since even research-grade EEG is hard to analyze in real time. That is a consumer product with company-led validation, not a medical device and not a clinical tool. If you track this field professionally, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> gives you the structured intelligence feed to go deeper than any single article can.</p><h2>Reading your results without fooling yourself</h2><p>Caffeine is the easiest confounder to catch. A randomized crossover trial summarized by Soon found that <strong>400 mg of caffeine six hours before bed cut monitored sleep by 1.18 hours</strong>, and participants&#8217; diaries <a href="https://soon.works/research/does-caffeine-reduce-night-shift-errors">did not detect the loss</a>. That is where a tracker can beat your own impression. But the effect is not guaranteed to show up on a wrist. In the small SleepSmart cohort of 40 adults, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12073117/">wearable data showed no significant sleep deterioration</a> while subjective sleep quality got worse. When your ring and your gut disagree, log both and keep the experiment running.</p><p>Then apply three decision rules. If one block wins by a clear margin across most days, protect it: no meetings, notifications off. If your hourly curve is flat, stop hunting for a window and protect sleep, because the sleep evidence is stronger than the timing evidence. If a low-HRV morning keeps preceding a bad block, shift that day&#8217;s hardest task rather than forcing it.</p><p>Which hour do you suspect is secretly your best, and what would it take to run your hardest work there for the next fourteen days?</p>]]></content:encoded></item><item><title><![CDATA[NeuroTech in 5 Minutes: 7 Terms You Need So You Never Feel Lost Again]]></title><description><![CDATA[A Neuralink update, a Synchron press release and a Meta preprint can all say "brain-computer interface" while describing three very different stages of maturity.]]></description><link>https://www.neurotechmag.com/p/neurotech-in-5-minutes-7-terms-you</link><guid isPermaLink="false">https://www.neurotechmag.com/p/neurotech-in-5-minutes-7-terms-you</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Wed, 11 Nov 2026 14:57:29 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!e4Er!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!e4Er!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!e4Er!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!e4Er!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!e4Er!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!e4Er!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!e4Er!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2546849,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/222502936?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!e4Er!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!e4Er!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!e4Er!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!e4Er!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F393b9202-667e-49e0-abb7-c57c3ba6f07e_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Most confusion in this field comes from vocabulary. The same phrase covers a 2025 lab demo in healthy volunteers and a device implanted in a person with ALS under an FDA exemption. Once you know seven terms, you can place almost any headline on the ladder: lab demo, early clinical trial, cleared for use, on the market. Here is the list, with real devices and numbers as of late October 2026:</p><ul><li><p><strong>Brain-computer interface (BCI)</strong></p></li><li><p><strong>Electrode array and channel count</strong></p></li><li><p><strong>Invasive versus non-invasive</strong></p></li><li><p><strong>Decoding and word error rate</strong></p></li><li><p><strong>Investigational device exemption (IDE)</strong></p></li><li><p><strong>Breakthrough Device designation</strong></p></li><li><p><strong>510(k) clearance versus PMA</strong></p></li></ul><h2>Brain-computer interface and the ladder</h2><p>A <strong>brain-computer interface</strong> records neural activity, decodes what the person intends, and turns that into a command for an external device: a cursor, a speech synthesizer, a robotic arm. Some systems also stimulate the brain, which makes them <em>bidirectional</em>. The term says nothing about maturity, and that is the problem.</p><p>Take <strong>Neuralink</strong>. The company told Reuters in January 2026 that it had <a href="https://gvwire.com/?p=229932">21 participants enrolled in trials worldwide</a>, with zero serious device-related adverse events. Both figures are company-reported. The device is investigational. It is not a commercial product, whatever the &#8220;high-volume production&#8221; talk implies. No permanently implanted BCI has reached FDA premarket approval yet.</p><p>So every time a story says a BCI &#8220;works,&#8221; ask which rung it is on. A paper, a first-in-human implant, a cleared component and an approved system are four different claims. Which of those four do you see most often blurred together in your own feed?</p><h2>Electrode arrays and channel count</h2><p>The <strong>electrode array</strong> is the part that touches (or sits near) the brain. <strong>Channel count</strong> is how many separate recording sites it has. The oldest human workhorse is the <strong>Utah array</strong>: <a href="https://blackrockneurotech.com/products/utah-array/">96 electrodes per array</a>, silicon needles up to 1.5 mm long, made by Blackrock Neurotech and implanted in people since 2004. A <a href="https://www.medrxiv.org/content/10.1101/2025.07.02.25330310.full.pdf">medRxiv preprint</a> on the BrainGate trials covers 14 participants enrolled between 2004 and 2019, each with one or two arrays.</p><p>Newer devices push the numbers up:</p><ul><li><p><strong>Neuralink N1:</strong> 1,024 electrodes on 64 threads, inserted into cortex by a surgical robot</p></li><li><p><strong>Precision Neuroscience Layer 7:</strong> 1,024 electrodes on a thin film <a href="https://www.massdevice.com/?p=106342">one-fifth the thickness of a human hair</a>, resting on the cortical surface</p></li><li><p><strong>Paradromics Connexus:</strong> <strong>421 microelectrodes</strong>, recording from individual neurons</p></li><li><p><strong>Synchron Stentrode:</strong> <strong>16 electrodes</strong>, delivered through a vein</p></li></ul><p>Do not rank these by count alone. A penetrating electrode hears single neurons, a surface film hears populations, and a vein-mounted array hears from a distance. <em>Sixteen well-placed channels</em> can control a cursor. More channels buy bandwidth and finer decoding, but they cost surgical risk and engineering difficulty.</p><h2>Invasive, non-invasive, and the places between</h2><p><strong>Invasive</strong> usually means electrodes inside the skull. It splits into <strong>intracortical</strong> (penetrating the cortex, like the Utah array), <strong>electrocorticography or ECoG</strong> (on the cortical surface, like Precision&#8217;s film) and <strong>endovascular</strong> (inside a blood vessel, like Synchron&#8217;s catheter-delivered Stentrode). <strong>Non-invasive</strong> means sensors outside the head: <strong>EEG</strong> (scalp electrodes) or <strong>MEG</strong> (magnetic field sensing in a shielded room).</p><p>The trade is signal quality against surgery. Meta&#8217;s <strong>Brain2Qwerty</strong> shows both sides. The first version, from early 2025, used 35 healthy volunteers typing sentences. MEG gave an average <a href="https://circuitdigest.com/news/meta-ai-launches-brain2qwerty-a-non-invasive-method-to-convert-brain-signals-into-text">character error rate of 32%, while EEG gave 67%</a>. The newer v2 reports <a href="https://decrypt.co/372338">61% average word accuracy</a> from about 22,000 sentences across nine volunteers, each recorded for 10 hours. That is a real improvement over the roughly 8% of earlier non-invasive methods. It is also a <em>lab demonstration</em> in healthy people who physically type, using a scanner that needs a shielded room. Nobody is wearing that at home.</p><p>Keep medical and consumer separate here. A research MEG decoder, a Breakthrough-designated EEG headset for people with ALS (Cognixion&#8217;s ONE Axon is one), and a pair of focus-tracking EEG headphones are three different products with three different evidence bars.</p><h2>Decoding and word error rate</h2><p><strong>Decoding</strong> is the software step: a model maps neural features to an intended output. Its quality is reported as <strong>words per minute</strong>, <strong>word error rate (WER)</strong> and, critically, <strong>vocabulary size</strong>. Those three numbers only mean something together.</p><p>The 2023 <em>Nature</em> paper from Frank Willett and colleagues at Stanford reported <a href="https://pmc.ncbi.nlm.nih.gov/articles/10468393">62 words per minute with a 23.8% word error rate on a 125,000-word vocabulary</a>, in a participant with ALS. That was 3.4 times faster than the prior speech BCI, and the first large-vocabulary demonstration, though natural speech runs around 160 words per minute. A parallel ECoG study using a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10826467">253-channel high-density array</a> reached a median 78 words per minute at a median 25% WER.</p><p>Later intracortical work improved the error rates. A UC Davis system described in the <em>NEJM</em> paper reached 99.6% accuracy on a 50-word vocabulary on day one, after 30 minutes of attempted-speech training, and 97.5% accuracy beyond eight months, per the <a href="https://medrxiv.org/content/10.1101/2023.12.26.23300110v2">medRxiv version</a>. A 99.6% claim on 50 words and a 97.5% claim on a large vocabulary are different achievements. All of these results come from one or a handful of participants, so treat them as strong <em>proof of function</em>, not proof of a product.</p><h2>IDE, Breakthrough designation, and 510(k) versus PMA</h2><p>Three regulatory terms get confused constantly, so take them in order.</p><p>An <strong>investigational device exemption (IDE)</strong> lets an unapproved device be used in a clinical study. Many IDE studies are <strong>early feasibility studies (EFS)</strong>: small, safety-first, with efficacy only explored. <strong>Synchron&#8217;s COMMAND</strong> was the first IDE trial of a permanently implanted BCI. In six patients it reported <a href="https://www.massdevice.com/synchron-command-study-results-stentrode-bci-implant/">no device-related serious adverse events causing death or permanent increased disability</a> over 12 months. <strong>Paradromics</strong> received its IDE in November 2025, and its first Connect-One implant took place on June 17, 2026 at the University of Michigan. The first participant has motor neuron disease and <a href="https://www.uofmhealth.org/news-release/university-michigan-implants-first-human-paradromics-wireless-brain-computer-interface-designed">will be followed for six years</a>. Every paper, funding round, and trial update we report on ends up summarized and searchable in <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> if you want to track programs like these across their full timelines.</p><p><strong>Breakthrough Device designation</strong> is a voluntary FDA program that gives prioritized review and more frequent FDA contact for devices targeting life-threatening or irreversibly debilitating conditions. It is a <em>development accelerator</em>, not an approval. Synchron, Neuralink, Precision, Blackrock and Cognixion hold designations, and CorTec added one in April 2026 for <a href="https://neuronewsinternational.com/?p=15364">stroke rehabilitation with its Brain Interchange system</a>.</p><p>Finally, <strong>510(k) clearance</strong> means FDA found a device substantially equivalent to an existing one. <strong>PMA (premarket approval)</strong> is the full approval route and demands a confirmatory trial showing safety and effectiveness. Precision&#8217;s Layer 7 got a <a href="https://www.medtechdive.com/news/precision-neuroscience-brain-implant-fda-cleared/745913/">510(k) in April 2025</a> for up to 30 days of implantation, which is real and useful. But that clears the electrode array, not the fully implantable wireless system still in development. Synchron says its path to a PMA runs through a 2026 confirmatory trial, funded by a $200 million Series D announced November 6, 2025. I found no confirmation that enrollment has begun, so that remains a plan, and the timeline depends on what the trial shows.</p><p>If you build in this space, learn to say which rung your device is on before anyone asks. And if you read BCI news weekly, which of these seven terms still trips you up?</p>]]></content:encoded></item><item><title><![CDATA[5 Things to Know Before Considering a Brain Implant for Chronic Pain]]></title><description><![CDATA[Closed-loop deep brain stimulation has a promising six-person result and a 65-year record of disappointments, and nothing in the field is approved for pain.]]></description><link>https://www.neurotechmag.com/p/5-things-to-know-before-considering</link><guid isPermaLink="false">https://www.neurotechmag.com/p/5-things-to-know-before-considering</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Fri, 06 Nov 2026 10:46:31 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!4QGc!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!4QGc!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!4QGc!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!4QGc!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!4QGc!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!4QGc!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!4QGc!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2595615,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/221291415?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!4QGc!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!4QGc!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!4QGc!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!4QGc!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F168b0ea6-20b1-4002-9bad-aaf26153565a_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>About 20% of US adults live with chronic pain, an estimated 50 million people, according to CDC figures cited in a <em><a href="https://www.nytimes.com/2025/08/14/health/pain-personalized-brain-stimulation.html">New York Times</a></em><a href="https://www.nytimes.com/2025/08/14/health/pain-personalized-brain-stimulation.html"> report on personalized brain stimulation</a>. For the small group whose pain survives every drug, nerve block, and spinal implant, a brain implant sounds like the last door. That door is still being built.</p><p>This technology is <strong>medical</strong>, not consumer, and it sits at the <em>early clinical trial</em> rung. The strongest recent result comes from a feasibility study of six people. Here are five things worth knowing before the idea turns into a hope.</p><h2>1. No brain implant is approved for chronic pain</h2><p>Deep brain stimulation (DBS) has had FDA approval for Parkinson&#8217;s disease since <strong>2002</strong>. Pain is a different story. A <a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1683991/pdf">2025 review in </a><em><a href="https://public-pages-files-2025.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1683991/pdf">Frontiers in Medicine</a></em> says DBS for pain has stayed <strong>off-label</strong> since the FDA approval was withdrawn after the late 1970s. A <a href="https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2023.1297894/full">2023 systematic review</a> adds that the push for approval ended after two multicenter studies. UCSF&#8217;s Prasad Shirvalkar told the <em>New York Times</em> that results were inconsistent, with some patients getting no help and others losing relief over time.</p><p>Here is where each approach sits. Conventional DBS for pain is an off-label procedure at specialist centers. Closed-loop DBS for pain is an <strong>early feasibility study</strong> run under an FDA <strong>Investigational Device Exemption</strong>. <em>Nothing</em> in this category is a product you can buy. Policy outside the US is no looser: as of its <a href="https://www.engage.england.nhs.uk/consultation/clinical-commissioning-wave8/user_uploads/d08x07-evidence-rev.pdf">2015 clinical commissioning policy</a>, NHS England did not routinely commission DBS for chronic neuropathic pain.</p><h2>2. The best recent result is six people and a preprint</h2><p>The groundwork was a 2023 <em><a href="https://www.iasp-pain.org/publications/pain-research-forum/papers-of-the-week/paper/first-in-human-prediction-of-chronic-pain-state-using-intracranial-neural-biomarkers/">Nature Neuroscience</a></em><a href="https://www.iasp-pain.org/publications/pain-research-forum/papers-of-the-week/paper/first-in-human-prediction-of-chronic-pain-state-using-intracranial-neural-biomarkers/"> study</a> from Shirvalkar and Edward Chang&#8217;s group at UCSF. They implanted electrodes in the anterior cingulate and orbitofrontal cortex of four people and predicted chronic pain severity from orbitofrontal activity. The follow-up is the PRISM trial, posted as a <a href="https://www.medrxiv.org/content/10.1101/2025.08.11.25333010.full.pdf">medRxiv preprint in August 2025</a>. It had not been through peer review when posted, and I could not find a peer-reviewed version. The design:</p><ul><li><p><strong>Participants:</strong> six adults aged 48 to 58 with refractory pain (three post-stroke, one chemotherapy-induced neuropathy, one complex regional pain syndrome, one spinal cord injury).</p></li><li><p><strong>Mapping phase:</strong> 10 days of temporary electrodes, with up to 14 candidate sites per hemisphere tested for stimulation targets and pain biomarkers.</p></li><li><p><strong>Permanent implant:</strong> five participants received two Medtronic Summit RC+S systems and four 4-contact leads each, sensing at 250 Hz on four bipolar channels per device.</p></li><li><p><strong>Follow-up:</strong> up to 3.5 years.</p></li></ul><p>In the double-blind crossover phase, closed-loop stimulation cut average daily pain by about <strong>50%</strong> (range 12 to 87%). Sham was associated with a mean 11% increase. Step counts rose 18% versus 1%, and the system stimulated only <strong>7 to 55%</strong> of the time, where conventional DBS is always on. News coverage cited roughly 60%, but the preprint&#8217;s group figure is the lower number, so use that one.</p><p>The caveats decide how much weight this carries. Sham testing happened in <strong>four of five</strong> participants because one declined it. Nobody compared closed-loop with continuous stimulation, so the study does not show that the &#8220;thermostat&#8221; matters, a point Shirvalkar and Cleveland Clinic&#8217;s Andre Machado both made to the <em>Times</em>. The authors also hold a <strong>patent</strong> on closed-loop DBS for pain, and Medtronic donated the hardware without a role in the analysis, per the preprint. For the full research, funding, and trial picture behind this story, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> has you covered.</p><p>If you are building in this space, the open question is the one the authors flag: is biomarker-driven control <em>necessary</em>, or would timed stimulation do just as well?</p><h2>3. Older brain targets have a thin controlled record</h2><p>Before PRISM, the main targets were the sensory thalamus, periaqueductal grey, anterior cingulate, and motor cortex. A <a href="https://pubmed.ncbi.nlm.nih.gov/18991496">critical review of motor cortex stimulation</a> covered <strong>14 studies and 210 patients</strong>, all case series and <em>none controlled</em>. About 55% of operated patients had a good response. A later <a href="https://stanfordhealthcare.org/publications/323/323513.html">Stanford series of 14 patients</a> found only two still above 50% improvement at their last visit.</p><p>Cleveland Clinic ran one of the few randomized trials, in <strong><a href="https://www.rdworldonline.com/deep-brain-stimulation-shows-promise-for-chronic-pain/">ten patients</a></strong><a href="https://www.rdworldonline.com/deep-brain-stimulation-shows-promise-for-chronic-pain/"> with post-stroke pain</a>. The blinded phase showed no significant difference on the main disability measure, though affective measures improved, and the team planned a multicenter follow-up. A <a href="https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2023.1297894/full">meta-analysis of </a><strong><a href="https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2023.1297894/full">43 studies and 966 patients</a></strong> found a significant effect in people who received DBS for pain. The PRISM authors note that most earlier work was unblinded or lacked a placebo arm.</p><p>My read is that the field has more than 65 years of impressive case series and disappointing trials. PRISM is better designed than most of them, and it is <em>still</em> six people.</p><h2>4. The risks come from the surgery, and they are not small</h2><p><a href="https://www.nice.org.uk/guidance/htg253/chapter/2-The-procedure">NICE&#8217;s procedure guidance</a> cites a case series of 141 patients with infection in <strong>12%</strong>. Another series of 122 patients reported <em>ventriculitis</em> in one, subgaleal infection in four, and <em>subdural empyema</em> in one, and two of those patients needed the system removed. NICE&#8217;s specialist advisers also listed mood change from aberrant stimulation, speech difficulty, and lead migration. The motor cortex review above reported early postoperative <strong>seizures</strong> in 12% of patients.</p><p>PRISM reported serious surgical adverse events in <strong>two of six</strong> participants. One had an infection that required removing the device on one side of the brain, and another had speech problems that took months to resolve. A third participant had a brief seizure during the exploratory phase. The investigators reported <strong>no serious events from the stimulation itself</strong>.</p><h2>5. Know what else is on the table, and what to ask a trial team</h2><p>A brain implant is the <em>last step</em>, not the first. Spinal cord stimulation (SCS) is the nearer implant, and its evidence is contested. A <strong>Cochrane</strong> <a href="https://www.cochrane.org/about-us/news/spinal-cord-stimulation-doesnt-help-back-pain-says-new-review">review of 13 trials with 699 participants</a> found SCS probably does not improve low back pain against placebo at six months. It does not support using SCS for back pain outside clinical trials. A <a href="https://eprints.whiterose.ac.uk/id/eprint/241686/">2026 network meta-analysis</a> of 16 randomized trials found low to moderate certainty that SCS beats conventional medical management, and rated all but one trial at high risk of bias. The safest reading is that SCS looks better than <em>usual care</em> and is unproven against sham.</p><p>A non-invasive option is at pilot stage. A <a href="https://classic.clinicaltrials.gov/ct2/show/record/NCT05674903">low-intensity focused ultrasound trial</a> for generalized chronic pain listed an estimated primary completion of <strong>March 31, 2026</strong>, and I found no results yet.</p><p>On access, UCSF&#8217;s <a href="https://clinicaltrials.ucsf.edu/deep-brain-stimulation">deep brain stimulation trials page</a> listed a closed-loop pain study as open to eligible people aged 22 to 80 when I checked. PRISM enrolled people who had failed every therapy, rated baseline pain at 6 out of 10 or higher, and had no untreated psychological disorders. If you or someone you know is weighing a trial, a pain specialist should map the options first. Questions to bring to any team:</p><ul><li><p>How long is the sham phase, and when does a participant learn which condition they received?</p></li><li><p>What happens to the implanted hardware after the study ends?</p></li><li><p>What are the rules for removal if there is an infection or the device does not help?</p></li><li><p>What psychiatric and rehabilitation support comes with the surgery?</p></li></ul><p>So here is the question for the field. Should a six-person preprint with a 50% average reduction be enough to justify a multicenter trial, or does it need a continuous-stimulation arm first?</p>]]></content:encoded></item><item><title><![CDATA[How to Bring Neurofeedback Into Your Therapy Practice: A Starter Checklist]]></title><description><![CDATA[The hardware is easy to buy, but the regulatory, evidence, training, and billing questions decide whether it belongs in your office.]]></description><link>https://www.neurotechmag.com/p/how-to-bring-neurofeedback-into-your</link><guid isPermaLink="false">https://www.neurotechmag.com/p/how-to-bring-neurofeedback-into-your</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Thu, 05 Nov 2026 10:46:28 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!sD1o!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!sD1o!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!sD1o!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!sD1o!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!sD1o!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!sD1o!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!sD1o!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2482348,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/221291297?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!sD1o!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!sD1o!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!sD1o!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!sD1o!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F61fbb78c-6bf8-4c00-bf98-932938bba657_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Adding EEG neurofeedback to a therapy practice is a purchasing decision, a clinical decision, and a legal one, and most guides cover only the first. The equipment is <strong>commercially available</strong>, the training pathway is defined, and a CPT code exists. The condition-specific evidence is where it gets uncomfortable, and that is the part you need to settle before you tell a client what the sessions might do.</p><p>This checklist covers five things in order: what the device is cleared for, what the trials show for the conditions people ask about, what training and credentialing involve, how billing works, and what to record once you start. The short version is that neurofeedback is a <em>real</em> intervention with a <em>thin</em> controlled evidence base, and the gap between those two facts is your informed-consent conversation.</p><h2>Start with what the device is cleared to do</h2><p>Most clinical EEG neurofeedback systems sit under the FDA&#8217;s biofeedback device regulation, 21 CFR 882.5050, as <strong>Class II</strong> devices. The wording of the clearance is narrower than the marketing. A representative example is the <a href="https://510k.innolitics.com/device/K012011">Autogenics Model A620-3 clearance letter from 2001</a>, which lists general relaxation training as the indication for its EEG biofeedback instrument. Other devices under the same regulation carry relaxation and muscle reeducation indications.</p><p>That means &#8220;FDA-cleared&#8221; is accurate and also says nothing about ADHD, PTSD, or depression. The clearances I reviewed do not name those conditions. Before you buy, pull the 510(k) summary for the exact system and keep a copy in your practice file. If a vendor&#8217;s sales material describes a treatment claim that the clearance does not, ask for the document that supports it. A ladder note for your records: the device is <strong>on the market</strong> for relaxation training, and everything beyond that is clinical judgment backed by research-stage evidence.</p><h2>Match the evidence to the condition</h2><p>ADHD is the most-studied use, and the best data are unflattering. The 2016 <a href="https://eprints.nottingham.ac.uk/39737">meta-analysis from Samuele Cortese and the European ADHD Guidelines Group</a> pooled 13 trials with 520 participants. It found a significant effect on ratings from the people closest to treatment, an SMD of 0.35 for total symptoms. The effect disappeared when ratings came from probably blinded assessors or when trials used active or sham controls. A later <em><a href="https://iris.unica.it/bitstream/11584/442966/1/Westwood%20neurofeedback%202024.pdf">JAMA Psychiatry</a></em><a href="https://iris.unica.it/bitstream/11584/442966/1/Westwood%20neurofeedback%202024.pdf"> meta-analysis led by Samuel Westwood</a> restricted itself to probably blinded outcomes: 20 trials, 1,214 participants, an SMD of <strong>0.04</strong> (95% CI -0.10 to 0.18). The authors concluded that neurofeedback did not meaningfully benefit people with ADHD at the group level.</p><p>PTSD is less settled. A <a href="https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1658652/abstract">PROSPERO-registered meta-analysis in </a><em><a href="https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1658652/abstract">Frontiers in Neuroscience</a></em> published in December 2025 separated sham-controlled trials from waitlist and treatment-as-usual comparisons. Two sham-controlled fMRI neurofeedback RCTs showed no symptom improvement, and the authors argue that better controls are needed to know whether neurofeedback or something else drives the gains. fMRI is not what a private practice runs, but the control-design problem carries over to EEG work. For depression, a February 2026 narrative review of 15 trials reports promising alpha asymmetry and peak alpha protocols. A narrative review pools nothing, so treat it as a list of leads rather than an effect size.</p><p>If you follow this field professionally, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> gives you the structured intelligence feed to go deeper than any single article can. In the meantime, look at your own caseload. Which of your clients&#8217; goals rest on blinded evidence, and which rest on the unblinded kind that shrinks under sham control?</p><p>Not everyone reads this evidence the same way. <a href="https://www.brainfutures.org/neurofeedback-info-for-providers/">BrainFutures&#8217; provider page</a> argues that neurofeedback should be considered first-line for ADHD. That position conflicts with the blinded meta-analyses above, and a client searching online will meet both. Be ready to explain why you side with one.</p><h2>Get trained, and keep your license in front</h2><p>Neurofeedback training sits on top of your existing professional license and does not replace it. The main credential is <strong>BCIA board certification</strong>, which <a href="https://biosourcesoftware.com/bcia-certification">BioSource Software&#8217;s overview</a> notes is not a substitute for a state license. <a href="https://biosourcesoftware.com/bcia-neurofeedback-certification">BCIA&#8217;s neurofeedback pathway</a> requires an approved health-care degree, <strong>36 hours of didactic education</strong>, <strong>25 contact hours with an approved mentor</strong> that include 10 sessions of your own neurofeedback, and an exam. Published filing and certification fees were $150 and $300 when I checked, so confirm current numbers with BCIA.</p><p>Equipment is the larger cost. A <a href="https://traumaresearchfoundation.org/?p=29283">Trauma Research Foundation page from 2021</a> listed a base equipment price of $7,500 alongside a $1,600 course and practicum. Treat that as a dated reference point rather than a quote. Ask your malpractice carrier whether neurofeedback is covered under your current policy, and get the answer in writing.</p><h2>Sort out billing before the first session</h2><p>There is no neurofeedback-specific CPT code. Practices generally bill <strong>CPT 90901</strong>, biofeedback training by any modality, and a <em><a href="https://www.neuroregulation.org/article/view/23552">NeuroRegulation</a></em><a href="https://www.neuroregulation.org/article/view/23552"> article on ethical billing</a> covers the history of the codes, Medicare&#8217;s position, incident-to rules, and recent fraud cases. Read it before you hire a biller. Documentation has to support each claim, and technician-delivered sessions raise supervision questions.</p><p>Coverage is patchy. <a href="https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/cpg294_biofeedback.pdf">Cigna&#8217;s biofeedback policy</a> lists EEG biofeedback and neurofeedback as experimental, investigational, or unproven for any indication. BrainFutures says at least 12 states have plans that cover it, though its page is an advocacy source. A Delaware clinic described in <a href="https://technical.ly/startups/enhanced-edge-delaware-mental-health/">a Technical.ly profile</a> charged about $100 per session and did not bill insurance. If you have ever submitted a 90901 claim for neurofeedback, pull one denial and read the stated reason. It will tell you more about your payer mix than any vendor brochure.</p><h2>The starter checklist</h2><p>Researchers have already written the reporting standard you can borrow. The <a href="https://gala.gre.ac.uk/id/eprint/27068/">CRED-nf consensus checklist in </a><em><a href="https://gala.gre.ac.uk/id/eprint/27068/">Brain</a></em> asks for control conditions, blinded outcome raters, a record of whether participants received a strategy and what they used, and a report of whether people actually learned to regulate the targeted signal. Most of that translates into a practice setting with modest effort.</p><ul><li><p><strong>Device file:</strong> the 510(k) number, the cleared indication, and the vendor&#8217;s support documents.</p></li><li><p><strong>Credentials:</strong> license scope confirmed, BCIA status or a training plan, and malpractice coverage in writing.</p></li><li><p><strong>Consent:</strong> a plain statement of the evidence level for the client&#8217;s target condition, including the blinded-outcome results.</p></li><li><p><strong>Outcome plan:</strong> a standardized measure at baseline and at a pre-agreed review point, ideally scored by someone other than the treating clinician.</p></li><li><p><strong>Session record:</strong> protocol, electrode site, frequency band, session count, and whether the client reached regulation of the feedback signal.</p></li><li><p><strong>Billing check:</strong> payer policy confirmed in writing, 90901 documentation reviewed, and a plan for self-pay clients.</p></li></ul><p>If you are building a clinic around this, the expensive mistake is a business plan that assumes the ADHD claim holds. Whether neurofeedback ever earns that claim will depend on larger preregistered, double-blind trials with sham arms, and the field has not produced them yet. Until then, which of your current clients&#8217; goals would still stand if you counted only the blinded evidence?</p>]]></content:encoded></item><item><title><![CDATA[How to Use Brain Training Tech to Actually Remember What You Study]]></title><description><![CDATA[Neurofeedback, brain stimulation, and sleep devices all promise better recall, and the evidence behind each is thinner than the marketing.]]></description><link>https://www.neurotechmag.com/p/how-to-use-brain-training-tech-to</link><guid isPermaLink="false">https://www.neurotechmag.com/p/how-to-use-brain-training-tech-to</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Wed, 04 Nov 2026 10:45:37 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!5p6c!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!5p6c!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!5p6c!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!5p6c!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!5p6c!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!5p6c!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!5p6c!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2109676,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/221291256?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!5p6c!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!5p6c!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!5p6c!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!5p6c!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F219cdcc4-c81f-4b08-95ce-c47d354eacc1_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Students looking for a memory edge are being sold three kinds of neurotechnology: headsets that train your brain rhythms, electrodes that push current through your scalp, and headbands that play sounds while you sleep. None of them is a <strong>study method</strong> yet. Each has a real research literature, and each literature is smaller and messier than the product pages suggest.</p><p>This piece sorts the three by how much evidence sits behind the memory claim, then says what to do with that. The short version: the effects are <em>small</em>, the best results come from labs rather than consumer devices, and the thing most likely to help on your exam is still the studying.</p><h2>Where each technology sits on the ladder</h2><p>The marketing flattens the ladder, so here is where each approach actually stands:</p><ul><li><p><strong>EEG neurofeedback:</strong> <em>early research.</em> Small randomized trials and one pooled analysis in preprint, with no regulatory pathway for a memory claim.</p></li><li><p><strong>tACS (transcranial alternating current stimulation):</strong> <em>lab demonstrations</em> in healthy older adults at Boston University. I found no cleared or commercial memory product built on it.</p></li><li><p><strong>tDCS (transcranial direct current stimulation):</strong> <em>mixed lab evidence</em>, with consumer devices sold under wellness language.</p></li><li><p><strong>Closed-loop acoustic stimulation during sleep:</strong> <em>lab studies in humans</em>, plus a consumer headband from <strong>Elemind</strong> aimed at sleep onset, with memory work still in research collaborations.</p></li></ul><p>Almost every positive result below comes from a lab or a clinical population. A student wearing a headset at a desk is a different experiment, and nobody has run it at scale.</p><h2>Neurofeedback works a little, and not better than practice</h2><p>The most useful single document on neurofeedback and memory is a <a href="https://www.biorxiv.org/content/10.1101/2025.11.03.685283.full.pdf">systematic review and meta-analysis posted to bioRxiv</a> in November 2025. It is a <em>preprint</em>, so it has not been through peer review. The authors screened 3,927 articles, kept 44 for qualitative synthesis, and pooled <strong>73 randomized comparisons from 24 studies covering 649 healthy adults</strong>. The pooled effect was <strong>a standardized mean difference of 0.28</strong> (95% CI 0.065 to 0.48). That is small, statistically significant, and far from what a headset box implies.</p><p>The details cut both ways. <strong>Alpha-band training</strong> showed an effect of 0.39. Short-term and verbal memory improved, while long-term memory did not reach significance. Younger adults showed an effect of 0.29, and older adults showed nothing distinguishable from zero, though only four studies covered them. Against sham feedback, neurofeedback won a little. Against general cognitive training it did not clearly win. A real headset beat a fake headset, but it did not beat <em>practicing</em>.</p><p>The caveats matter as much as the numbers. Only one included study was preregistered, most measured memory within 24 hours of the last session, and the literature search ran in September 2022, so the last four years of work are missing. Effects above 0.2 appeared only for sessions longer than 30 minutes, a dose finding the authors call marginal.</p><p>A typical single trial looks like a <em>Memory</em> study from Jonathan Guez and colleagues: <a href="https://cris.huji.ac.il/en/publications/influence-of-electroencephalography-neurofeedback-training-on-epi/">30 volunteers, ten 30-minute sessions, and a sham arm</a>. Sensorimotor rhythm training improved familiarity-based memory, and upper alpha training improved recollection. Sorting which of these small trials were preregistered or replicated is tedious work. Every paper, funding round, and trial update we report on ends up summarized and searchable in <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a>.</p><p>If you have run a consumer neurofeedback headset through a semester, ask what you measured beyond how focused you felt. A baseline quiz on matched material takes ten minutes and tells you more than the app&#8217;s score.</p><h2>Brain stimulation: strong lab results, no student product</h2><p>The strongest non-invasive stimulation result in humans comes from Robert Reinhart&#8217;s lab at Boston University. In 2019 the team reported in <em>Nature Neuroscience</em> that 25 minutes of individualized HD-tACS, tuned to frontotemporal theta synchronization, <a href="https://www.advisory.com/daily-briefing/2019/04/11/memory">brought older adults&#8217; working memory up to the level of young adults</a> in the lab. The effect lasted about 50 minutes.</p><p>The follow-up was more interesting. In a <a href="https://www.nih.gov/node/17721">September 2022 </a><em><a href="https://www.nih.gov/node/17721">Nature Neuroscience</a></em><a href="https://www.nih.gov/node/17721"> paper</a>, low-frequency stimulation over the parietal region improved <strong>working memory</strong>, while high-frequency stimulation over prefrontal cortex improved <strong>long-term memory</strong>. Both gains were still visible a month later. Oxford&#8217;s Masud Husain put the size at roughly three to four extra words from a list of 20, as <a href="https://beingpatient.com/electric-jolt-may-boost-memory/">reported by Being Patient</a>, and noted that participants were stimulated <em>while</em> doing the memory task. It is a durable lab effect in adults aged 65 to 88. It is not a study aid for a twenty-year-old.</p><p>tDCS is the cheaper cousin, and its record is noisier. An <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8511213">electric-field-modeling meta-analysis of 87 experiments</a> found small overall working-memory effects, with much of the variability traced to differences in electrode position, size, and intensity. One device name hides many different experiments.</p><p>The regulatory picture is loose. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6629579">2019 review of direct-to-consumer neurotechnology</a> noted that FDA guidance on low-risk wellness products suggested consumer tDCS falls within the agency&#8217;s jurisdiction, yet no public enforcement action had followed. If you are building in this space, the tDCS record is the warning: standardize the montage and publish the dose, or the next meta-analysis will average your result into noise.</p><h2>Sleep has the best mechanism and mixed device results</h2><p>Sleep is the one place where the biology is on your side. Slow oscillations, spindles, and hippocampal ripples are the rhythms tied to memory consolidation, and a <a href="https://www.frontiersin.org/articles/10.3389/fnins.2025.1682450">February 2026 review in </a><em><a href="https://www.frontiersin.org/articles/10.3389/fnins.2025.1682450">Frontiers in Neuroscience</a></em> lays out how closed-loop systems try to boost them with precisely timed sound or current.</p><p>The weak step is the one from rhythm to recall. Acoustic stimulation reliably boosts slow-oscillation activity in humans, but memory outcomes vary. In a nap study of <a href="https://par.nsf.gov/biblio/10488451">16 healthy young adults</a>, closed-loop sound increased slow oscillatory and spindle activity and left post-nap learning unchanged at the group level. The authors suspect time of day and individual cognitive ability play a role.</p><p>Timing is probably the lever. A <a href="https://pubmed.ncbi.nlm.nih.gov/36279449/">2022 </a><em><a href="https://pubmed.ncbi.nlm.nih.gov/36279449/">PNAS</a></em><a href="https://pubmed.ncbi.nlm.nih.gov/36279449/"> study</a> delivered memory reminder cues at specific phases of the slow oscillation, treating phase as a controlled variable instead of ignoring it. That is the right direction, and it is still lab work.</p><p>Consumer hardware sits behind that work. <a href="https://news.mit.edu/2024/startup-elemind-helps-people-fall-asleep-0925">Elemind&#8217;s EEG headband</a> reads brainwaves and plays tones through a bone conduction driver. In a small study of adults with sleep-onset insomnia, 30 minutes of stimulation cut the time to fall asleep by 10 to 15 minutes. Memory is a stated future goal. MIT News also reports a McGill result showing better memory-task performance after stimulation during sleep, but a peer-reviewed paper was not among the sources checked, so treat it as <strong>reported, not confirmed</strong>.</p><h2>What to do with all of this</h2><p>For a student, the order of operations is plain. Do the studying first, because neurofeedback did not clearly beat general cognitive training and no stimulation protocol has a student-ready product. Protect the <strong>sleep that follows</strong>, since consolidation is the process the whole closed-loop field is trying to amplify. If you buy a device anyway, run it as an experiment on yourself: learn matched material with and without it, test after a delay, and ignore the dashboard score.</p><p>For anyone tracking the field, the signals worth waiting for are specific. Look for <strong>preregistered, double-blind trials</strong> with delayed memory tests, young and old cohorts reported separately, and stimulation parameters published in full. Closed-loop sleep stimulation may reach a regulated product first, pending a trial that shows a benefit on a next-day test rather than only a larger slow wave.</p><p>So which result would you actually pay for: a headband that raises your slow-wave power, or one that moves your score on Monday&#8217;s exam?</p>]]></content:encoded></item><item><title><![CDATA[How to Break Into the Neurotech Industry With Zero Neuroscience Background]]></title><description><![CDATA[Most open roles at brain-computer interface companies ask for engineering, quality, and regulatory skills, not a neuroscience degree.]]></description><link>https://www.neurotechmag.com/p/how-to-break-into-the-neurotech-industry</link><guid isPermaLink="false">https://www.neurotechmag.com/p/how-to-break-into-the-neurotech-industry</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Fri, 30 Oct 2026 09:57:32 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!QIAr!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!QIAr!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!QIAr!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!QIAr!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!QIAr!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!QIAr!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!QIAr!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2473249,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/220333661?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!QIAr!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!QIAr!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!QIAr!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!QIAr!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a0d6b8c-f801-47ef-b486-589b3b8152ef_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>I keep hearing the same worry from readers: &#8220;I love this field, but I never studied the brain.&#8221; Fair concern, wrong conclusion. Walk through the careers pages of the companies building implants and you find a hiring list that looks a lot more like a medical device company than a neuroscience department. The catch is that medical device work has its own demanding vocabulary, and that is the homework you actually need to do.</p><h2>The jobs are mostly not neuroscience jobs &#129504;</h2><p>Start with what companies are posting right now. <strong>Epia Neuro</strong>, a BCI company building intent-driven systems, <a href="https://www.metaintro.com/company/epianeuro">lists 11 open roles</a> as of October 6, 2026. The list includes an <strong>ASIC design engineer</strong>, a <strong>staff robotics hardware engineer</strong>, a <strong>senior quality engineer</strong>, a <strong>staff ML engineer</strong>, and a technical project manager for software and firmware. Not one of those titles says &#8220;neuroscientist.&#8221; &#9881;&#65039;</p><p><strong>Science Corp</strong>, a clinical-stage company in Alameda that is building closed-loop BCIs, is even blunter. Its software posting says <a href="https://jobs.dukecapitalpartners.duke.edu/companies/science-2-c51ad5de-bca3-4e36-ade1-1263f4951df2/jobs/68487782-software-bci">you don&#8217;t necessarily need a neuroscience background</a>, and it lists <strong>$130K to $200K</strong> plus equity. What it wants instead is <em>high-throughput data handling under strict latency requirements</em>. That is a systems engineering problem that happens to sit next to a brain. &#128187;</p><p>Neuralink said the same thing in its early hiring push, when it told applicants that <a href="https://inverse.com/article/30596-elon-musk-neuralink-job-openings">&#8220;No neuroscience experience is required&#8221;</a> for its engineering and science openings. I&#8217;d treat that as culture signaling more than a promise, since the senior science roles still want depth. Still, the door is open for builders.</p><p>Roles that routinely show up without a neuroscience prerequisite:</p><ul><li><p><strong>Embedded and firmware engineers</strong> for implant electronics and external processors</p></li><li><p><strong>Full-stack and cloud engineers</strong> for clinical software and data platforms</p></li><li><p><strong>Mechanical and manufacturing engineers</strong> for surgical tooling and pilot production</p></li><li><p><strong>Quality and human factors engineers</strong>, such as the human factors role at Barcelona-based <a href="https://inbrain-neuroelectronics.jobs.personio.com/">InBrain Neuroelectronics</a></p></li><li><p><strong>Technical program managers</strong> who keep a hardware, software, and clinical plan moving in one direction</p></li></ul><p>What&#8217;s your strongest transferable skill? Hold that thought, because the next section decides how you pitch it.</p><h2>Regulated-device skills are the real currency &#128203;</h2><p>Here is the part most career guides skip. These companies are not shipping apps. They are running <strong>FDA investigational device exemption (IDE)</strong> studies, and the people who know that process are scarce. &#128300;</p><p>Look at how specific the postings get. Neuralink&#8217;s <strong>Regulatory Engineer</strong> role, listed at <a href="https://startup.jobs/regulatory-engineer-neuralink-7990442">$71,000 to $119,000</a>, asks for IDE and PMA submissions and Class II/III device experience. Its <strong>Clinical Research Associate</strong> role <a href="https://wellfound.com/jobs/4025821-clinical-research-associate">wants 5+ years</a> and fluency in <strong>ISO 14155</strong> and <strong>21 CFR Part 812</strong>. <a href="https://www.builtinnyc.com/job/full-stack-software-engineer/9925929">Precision Neuroscience</a> asks its full-stack engineers to work inside an <strong>IEC 62304</strong> software lifecycle. None of that is taught in a neuroscience course. &#128200;</p><p>It also helps to know where the technology really stands, because job security follows regulatory stage:</p><ul><li><p><strong>Precision Neuroscience:</strong> the <strong>Layer 7 Cortical Interface</strong>, with 1,024 electrodes on a flexible film, received <a href="https://www.biospace.com/press-releases/precision-neuroscience-receives-fda-clearance-for-high-resolution-cortical-electrode-array">510(k) clearance in April 2025</a> for implantation up to 30 days. That is a cleared component, not a cleared chronic implant.</p></li><li><p><strong>Synchron:</strong> its <strong>Stentrode</strong> reached the end of the six-patient COMMAND early feasibility study with <a href="https://www.massdevice.com/synchron-command-study-results-stentrode-bci-implant/">no serious adverse events at 12 months</a>, and the company says it is working toward a larger US trial.</p></li><li><p><strong>Paradromics:</strong> the FDA <a href="https://www.statnews.com/2025/11/20/fda-approves-paradromics-bci-trial-for-speech-restoration/">approved a small speech-restoration study</a> of its Connexus implant in November 2025, with two planned participants.</p></li><li><p><strong>Neuralink:</strong> a securities filing says it <a href="https://www.sec.gov/Archives/edgar/data/0000840715/000175392626001386/MainDocument.htm">had 26 trial participants</a> as of June 30, 2026.</p></li></ul><p>As far as I can tell, no implanted BCI has full premarket approval yet. So every one of these companies still needs people who can get a device through the process. If you have <strong>medical device quality or regulatory experience from any field</strong>, you are closer to a neurotech job than you think. &#128640;</p><h2>Learn the vocabulary without the PhD &#127891;</h2><p>You do need to talk credibly with the neuroscientists on the team. That means knowing what an <strong>electrode array</strong> does, why <strong>spike sorting</strong> exists, and what <strong>latency</strong> and <strong>bandwidth</strong> mean for a decoder. You can pick that up in months, not years. &#128225;</p><p>Formal and free options that exist today:</p><ul><li><p>The NIH-supported <a href="https://www.neurotechcourse.org">NeuroTech Course</a> has offered free online lectures and a certificate on translating and commercializing neural devices. Check whether the current cohort is running.</p></li><li><p>Carnegie Mellon&#8217;s <a href="https://www.cmu.edu/bme/Academics/undergraduate-programs/neuro_track.html">neuroengineering track</a> lists neural signal processing and neural data analysis courses, which is a decent syllabus to copy even if you never enroll.</p></li><li><p>The University of Washington&#8217;s <a href="https://centerforneurotech.uw.edu/2017/03/14/turning-student-neural-engineering-projects-into-viable-industry-products">Neural Engineering Tech Studio</a> has drawn business and biology students alongside engineers, which tells you the field does not only want one profile.</p></li></ul><p>One honest warning about scope. Nearly everything above is <strong>medical</strong>. Consumer wearables and defense work have different employers, different regulators, and different ethics conversations. Pick a lane before you tailor a resume, because a pitch aimed at implant clinical trials reads oddly in a consumer EEG headband interview. &#127911;</p><h2>Get in the room, then read the room &#129309;</h2><p>Skills get you interviews, but this field is small, and people hire people they have met. NeuroNYC ran a <a href="https://luma.com/fims30t8">fireside chat on the state of neurotech hiring</a> in February 2026 with OpenBCI founder Conor Russomanno and recruiter Chay Carter. Events like that are where you learn which teams are actually growing. &#128483;&#65039;</p><p>To keep your picture current between events, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> gives you the structured intelligence feed to go deeper than any single article can. Use whatever tracker you like, but track something: funding rounds and trial milestones tell you who is about to hire before the job post goes up. &#128161;</p><p>A practical order of operations:</p><ul><li><p>Pick one medical modality, such as cortical arrays, endovascular, or non-invasive stimulation</p></li><li><p>Read one company&#8217;s trial publications and regulatory announcements end to end</p></li><li><p>Rewrite your resume around <strong>regulated development, data pipelines, or clinical operations</strong>, whichever you already have</p></li><li><p>Apply to roles one rung below your seniority at a company with a live trial, since clinical-stage teams add headcount as studies expand</p></li></ul><p>Pay is not uniform, and the wide gap between a $71,000 regulatory posting and a $200K-plus staff ML role shows how much your starting lane matters. &#128176;</p><p>So which of your current skills would a BCI company pay for tomorrow, and what is the one gap you could close in the next ninety days?</p>]]></content:encoded></item><item><title><![CDATA[7 Neurotech Gifts for the Person Who Has Everything (Ranked by Actual Usefulness)]]></title><description><![CDATA[Most brain-sensing gadgets make better conversation pieces than daily tools, so here is the order in which they earn their price.]]></description><link>https://www.neurotechmag.com/p/7-neurotech-gifts-for-the-person-379</link><guid isPermaLink="false">https://www.neurotechmag.com/p/7-neurotech-gifts-for-the-person-379</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Thu, 29 Oct 2026 09:57:35 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!68BK!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!68BK!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!68BK!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!68BK!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!68BK!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!68BK!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!68BK!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2277309,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/220333611?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!68BK!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!68BK!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!68BK!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!68BK!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6ff04ad8-399b-4882-9ee1-c2b6cfad38de_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Consumer neurotech has a gift-guide problem. Every device on the shelf arrives with a confident press release, and almost none of them tell you how the recipient will feel about it in week six. &#127873; I ranked seven by how likely a real person is to keep using them, weighing price, evidence, and how much tinkering each one demands. Prices below are what I found in October 2026, and they move. Which one would you want to unwrap?</p><h2>How I ranked these, and one device I left off</h2><p>I scored each product on three things, and I kept the rules simple so you can argue with them.</p><ul><li><p><strong>Evidence:</strong> is there a trial, and who ran it? Company-run studies count, but they count for less &#128300;</p></li><li><p><strong>Daily friction:</strong> does it fit into a night or a workday, or does it need a ritual?</p></li><li><p><strong>Price against payoff:</strong> a $1,200 headset has to do much more than a $349 one</p></li><li><p><strong>Claims discipline:</strong> wellness wording earns trust, and disease wording on an unregulated device loses it</p></li></ul><p>One product is missing on purpose. Flow Neuroscience&#8217;s FL-100 is a tDCS headset with an FDA premarket approval (PMA P230024) for adults with moderate to severe major depression. The <a href="https://hlth.com/insights/news/flow-neuroscience-launches-fda-approved-at-home-depression-treatment-in-the-us">10-week EMPOWER trial behind it</a> reported 57% remission on active stimulation. It is also prescription-only, and it treats a medical condition. That makes it a <em>medical</em> device, not a present, and wrapping one up for a friend would be an odd way to say &#8220;I noticed.&#8221; &#129504; Everything below is consumer or developer hardware, and I keep those two lanes apart on purpose.</p><h2>Ranks 1 and 2: the sleep and focus headbands</h2><h3>1. Elemind sleep headband ($349)</h3><p>Elemind wins because it solves one problem people already have. The headband reads EEG and plays timed bursts of sound aimed at the trough of the alpha wave, which <a href="https://spectrum.ieee.org/elemind-neuromodulation">IEEE Spectrum describes</a> as the moment the brain is most excitable. The company reports <strong>five clinical studies</strong>, two of them on sleep, covering 112 subjects and 876 nights. In its sleep trial, <strong>76% of participants fell asleep faster</strong>, by 48% on average. &#128564;</p><p>Treat those as company numbers from small studies. A GearJunkie reviewer found the gains real but modest, and daily charging is a chore. Still, it comes with a 30-day return window, so a wrong guess costs little.</p><ul><li><p><strong>Stage:</strong> commercially available consumer wellness device</p></li><li><p><strong>Best for:</strong> anyone who already wears a sleep tracker and still lies awake</p></li><li><p><strong>Watch out for:</strong> the <em>modest</em> in modest results &#9888;&#65039;</p></li></ul><h3>2. Muse S Athena ($474.99)</h3><p>Athena is the most complete headband for the money. It packs <strong>4 EEG channels</strong> plus fNIRS, which reads blood oxygenation in the frontal cortex, so you get electrical activity and a blood-flow proxy from one band. The silver-thread dry electrodes are an upgrade over the older Muse S. &#128200; Muse&#8217;s <a href="https://choosemuse.com/products/muse-s-athena">own product page</a> cites a 2021 sleep study showing a 20% improvement on the Pittsburgh Sleep Quality Index against controls, which is again a company-cited result.</p><p>Reviews are split. Fans like the fNIRS training mode, while one sleep-headband tester expected better reliability at this price. Overnight mode also needs the headband and headphones on together, so it is not a no-effort gift. &#128161;</p><h2>Ranks 3 to 5: the tinkerer, the sleep zapper, the smart headphones</h2><h3>3. OpenBCI Ganglion and headband kit (roughly $975)</h3><p>This is the best pick for someone who likes to build things. The Ganglion board has <strong>4 channels at 200 Hz</strong>, and OpenBCI&#8217;s own <a href="https://docs.openbci.com/FAQ/HowProductsGoTogether">product guide</a> says the EEG headband kit is the budget option for frontal and temporal sites. The storefront lists the board at $624.99 and the headband kit at $349.99, and the Ganglion needs a separate dongle. &#128295;</p><p>It ranks third because the recipient has to want a project. There is no polished app, and OpenBCI labels these as evaluation boards for engineering and research, not medical devices. A coder with a free weekend will love it. Everyone else will not. &#129513;</p><ul><li><p><strong>Stage:</strong> open-source research hardware</p></li><li><p><strong>Signal note:</strong> the Ganglion filters out everything below 0.3 Hz</p></li><li><p><strong>Best for:</strong> hobbyists and students building their first BCI</p></li></ul><h3>4. Somnee smart sleep headband ($299)</h3><p>Somnee takes a more aggressive route than Elemind. It pairs EEG sensing with a 15-minute session of closed-loop <strong>tACS</strong> (transcranial alternating current stimulation) before bed. The company says a 1,500-night home pilot <a href="https://hitconsultant.net/?p=66185">halved the time to fall asleep</a> and cut tossing and turning by more than a third. I could not find an independent trial. &#127769; It is sold as a wellness product, not a cleared medical device, and Khosla Ventures led a $10 million seed extension in 2025.</p><p>Electrical stimulation to the head is a bigger ask than sound, even at low currents. Check with a doctor first if the recipient takes sleep or neurological medication.</p><h3>5. Neurable MW75 Neuro LT ($499)</h3><p>These are premium noise-cancelling headphones with <strong>12 soft-fabric EEG sensors</strong> in the earcups, from Neurable and Master &amp; Dynamic. The LT edition is 12% lighter and $200 cheaper than the original $699 model, and Neurable says users gain an average of 33% more focus time. &#127911; The catch is power: battery life drops from 22 hours to 10 to 13 hours with focus tracking on, per <a href="https://www.notebookcheck.net/Headphones-with-brain-tracking-via-EEG-Neurable-unveils-MW75-Neuro-LT.1128364.0.html">Notebookcheck</a>.</p><p>I rank it fifth because the output is <em>advice</em>, a nudge to take a break. One reviewer of the pricier original called the headphones heavy, expensive and not very useful. They read broad attention states, not thoughts, and that is worth saying out loud at the gifting table.</p><h2>Ranks 6 and 7: the earbuds and the developer headset</h2><h3>6. Emotiv MN8 ($399)</h3><p>The MN8 is a pair of earbuds with <strong>2 EEG channels</strong> on dry conductive elastomer, plus an SDK. Battery life is up to six hours, and the <a href="https://emotiv.com/products/mn8">Emotiv product page</a> pitches it for focus, stress and relaxation insights. Emotiv also states its products are for research and personal use only. &#129514; Two channels give a coarse read, and ear-based EEG sees a limited region of the head.</p><p>It is a fun, discreet way to start. It also sits low because it does less than Athena for roughly the same money.</p><ul><li><p><strong>Stage:</strong> commercially available, research and personal use</p></li><li><p><strong>Pairs with:</strong> Emotiv&#8217;s free app and developer tools</p></li><li><p><strong>Skip if:</strong> the recipient wants guided training, not raw data</p></li></ul><h3>7. Neurosity Crown (around $1,199)</h3><p>The Crown is the best hardware on this list and the hardest to justify as a present. It has <strong>8 EEG channels</strong> at CP3, C3, F5, PO3, PO4, F6, C4 and CP4, a 256 Hz sample rate, a noise floor of 0.25 uVrms, and an on-device N3 chipset, per the <a href="https://neurosity.co/tech-specs">Neurosity spec sheet</a>. It also offers a JavaScript SDK. &#128640; One reviewer lists it at $1,199.</p><p>It lands last for a general recipient and first for a developer who wants to build brain-aware apps. Two sentences of honest advice: buy this only for someone who has asked for it, and ask yourself whether they have the time to use it.</p><h2>Who gets what</h2><p>If you want the short version, match the gift to the person. A poor sleeper gets the Elemind. A data-curious meditator gets the Athena. A coder gets the OpenBCI kit or the Crown. Nobody gets a prescription device in a gift bag. &#127919;</p><p>If you&#8217;re following this area of neurotech professionally, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> gives you the structured intelligence feed to go deeper than any single article can. Whatever you pick, keep the receipt, because most of these companies publish their own trial numbers and the independent evidence is still thin.</p><p>So here is my question: would you rather give someone a device that sleeps for them, or one that shows them what their brain is doing?</p>]]></content:encoded></item><item><title><![CDATA[How to Build a Brain-Health Routine After 50 Using Neurotech]]></title><description><![CDATA[Only one tool in this space has a randomized, 20-year result behind it, so the rest of the shelf deserves a hard look.]]></description><link>https://www.neurotechmag.com/p/how-to-build-a-brain-health-routine</link><guid isPermaLink="false">https://www.neurotechmag.com/p/how-to-build-a-brain-health-routine</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Wed, 28 Oct 2026 09:56:33 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!qOT_!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!qOT_!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!qOT_!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!qOT_!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!qOT_!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!qOT_!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!qOT_!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2138368,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/220333567?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!qOT_!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!qOT_!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!qOT_!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!qOT_!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F11858691-022d-429c-9874-c2a0da1bd2f4_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Most advice on brain health after 50 lumps four different things together: a long-running trial result, a consumer gadget, a clinical-stage device, and a lab demo. They are not the same, and a routine built on all four as if they were equals is mostly a shopping list. &#129504; This piece sorts each tool by development stage first, then builds a routine from what holds up. I have opinions about where the evidence is strong and where it is not, and I think you should too. Which of these tools are already in your drawer?</p><h2>Start with the one result that has 20 years behind it</h2><p>The strongest data point is not a headset. It is software. The ACTIVE trial, funded by the NIH, randomized <strong>2,832 older adults</strong> in the late 1990s to memory, reasoning or speed-of-processing training, or to a control group. A 2026 follow-up reported that participants in the speed-training arm who also got booster sessions had a <strong>25% lower incidence of dementia diagnoses</strong> over two decades. The <a href="https://www.hopkinsmedicine.org/news/newsroom/news-releases/2026/02/cognitive-speed-training-linked-to-lower-dementia-incidence-up-to-20-years-later">Johns Hopkins summary of the follow-up</a> puts the raw numbers at 105 of 264 diagnosed in that arm versus 239 of 491 in the control group. &#128200;</p><p>Now the caveats, because this audience wants them. The memory and reasoning arms showed <strong>no significant effect</strong>. Diagnoses came from Medicare records, not from clinic exams. The exercise that worked is sold today as a subscription app, BrainHQ, by the company that commercialized it. And the authors themselves say only that the training has the <em>potential</em> to delay diagnosis. That is prevention-flavored evidence from a consumer product, not a treatment.</p><ul><li><p><strong>Stage:</strong> commercially available software, backed by a large randomized trial</p></li><li><p><strong>Trial dose:</strong> ten sessions of 60 to 75 minutes over about five weeks, plus boosters at one and three years</p></li><li><p><strong>What failed:</strong> memory and reasoning training, in the same trial</p></li><li><p><strong>What it is not:</strong> a cure, or a medical device claim &#9888;&#65039;</p></li></ul><p>I would put this first in any routine. It is cheap, it is low risk, and it is the only item here with randomized evidence on dementia diagnosis itself.</p><h2>Treat sleep as the wearable use case</h2><p>If you want a device on your head, sleep is where the logic is cleanest. Slow-wave sleep falls sharply with age, and <em>closed-loop acoustic stimulation</em> tries to reverse part of that: an EEG headband spots a slow wave and fires a short sound at the right moment to deepen it. &#128564;</p><p>The work so far is small and early. An ETH Zurich group built a home system called <a href="https://www.technologynetworks.com/neuroscience/news/wearable-headband-device-could-enhance-deep-sleep-360504">SleepLoop</a> and tested it in <strong>16 older adults</strong> over four weeks in a crossover design. It enhanced slow waves in most of them. A KU Leuven pilot used the Dreem2 headband, which carries <strong>five dry EEG electrodes</strong>, in 11 adults with mild to moderate Alzheimer&#8217;s. A registered pilot (NCT05987007) is comparing the same approach with CBT for insomnia in 50 people with amnestic mild cognitive impairment.</p><p>I am skeptical of the louder claims. One startup press release says a single night of stimulation lifted memory scores in adults over 65 by an average of 400%. That is a company figure from a small lab test, not a product result. <em>Feasible</em> is the right word for this field today, not <em>proven</em>. &#128300;</p><ul><li><p><strong>Stage:</strong> early clinical and pilot trials, with consumer-style hardware</p></li><li><p><strong>Sample sizes so far:</strong> 11 to 16 participants in the home studies above</p></li><li><p><strong>Medical versus wellness:</strong> at-home EEG headsets exist on both sides. Cumulus Neuroscience has an <a href="https://www.pharmashots.com/15283/cumulus-neuroscience-receives-the-us-fda%E2%80%99s-clearance">FDA 510(k) clearance</a> for a dry-sensor headset that sends data to a physician, which is a different product class from a wellness band</p></li><li><p><strong>Cheap version:</strong> track your sleep, fix the basics, and skip the stimulation until trials get larger</p></li></ul><h2>Brain stimulation: promising numbers, thin guardrails</h2><p>Electrical and light-based stimulation get the most hype, so this is where I would spend the most skepticism. &#9889;</p><p>Take tDCS (transcranial direct current stimulation). A 2024 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456488/">meta-analysis in Frontiers in Aging Neuroscience</a> found that tDCS paired with cognitive training improved working memory in healthy older adults, with a standardized mean difference of <strong>0.35</strong>. That is a modest, real-looking effect. But a 2025 meta-analysis in <em>Alzheimer&#8217;s Research &amp; Therapy</em> found that in people who already have cognitive impairment, tDCS improved global cognition without a significant gain in memory or executive function. Protocols vary too much between studies for anyone to hand you a home dose with confidence.</p><p>Transcranial photobiomodulation (tPBM), which shines near-infrared light through the scalp, is earlier still. One study from Xuanwu Hospital in Beijing found that <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514540/">seven days of tPBM improved working memory</a> in 61 healthy older adults, with the effect lasting at least three weeks. That is one site and a small group. Larger sham-controlled work is underway, including an NYU Langone trial of 70 older adults with traumatic brain injury (NCT06956404) that runs to 2028. &#128161;</p><ul><li><p><strong>tDCS stage:</strong> research, with mixed meta-analytic results</p></li><li><p><strong>tPBM stage:</strong> early trials, mostly small and single-site</p></li><li><p><strong>My read:</strong> the useful move is joining a registered trial, not buying a headset online</p></li><li><p><strong>Ask any seller:</strong> where is the sham-controlled trial in adults my age?</p></li></ul><h2>Gamma light and sound is a clinical-stage bet, not a purchase</h2><p>Cognito Therapeutics is the company to watch. Its Spectris system is a pair of glasses and headphones that deliver <strong>40 Hz</strong> light and sound to evoke gamma oscillations, used at home about an hour a day. This is a medical device for people with Alzheimer&#8217;s, not a wellness product for healthy 55-year-olds. &#128640;</p><p>The company&#8217;s feasibility study, OVERTURE, was a six-month randomized trial at five US sites that was not powered to show efficacy. A post hoc analysis by the company reported delays in functional and cognitive decline of roughly 4.8 and 4.6 months. Post hoc means the company went looking after the fact, so I treat it as a reason for the larger trial and not as a result. That trial is <a href="https://clinicaltrials.gov/study/NCT05637801">HOPE (NCT05637801)</a>, a randomized, double-blind, sham-controlled study of <strong>670 patients</strong> across more than 60 US sites. The device holds FDA Breakthrough Device Designation, and the company raised a $105 million Series C to fund the readout and a regulatory filing. &#128202;</p><p>Topline timing has slipped in coverage, from mid-2026 to later in the year, and I found no reported readout as of today. Developments like this rarely happen in isolation &#8212; <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> tracks the research, funding, and trials that surround them.</p><ul><li><p><strong>Stage:</strong> investigational, in a large late-stage trial</p></li><li><p><strong>Regulatory status:</strong> not cleared, with Breakthrough designation only</p></li><li><p><strong>Safety note from the company:</strong> no ARIA observed, the brain-swelling side effect seen with some amyloid drugs</p></li><li><p><strong>What to do now:</strong> if a family member has mild to moderate Alzheimer&#8217;s, ask their neurologist about trials</p></li></ul><h2>A routine you can run this month</h2><p>Here is the version I would run myself. It uses only items with real evidence or low downside, and it leaves the stimulation hardware on the shelf for now. &#9989;</p><ul><li><p><strong>Weeks 1 to 5:</strong> do speed-of-processing training in sessions of roughly an hour, mirroring the ACTIVE protocol, then plan boosters rather than stopping</p></li><li><p><strong>Every night:</strong> track sleep with a wearable and fix the boring causes first, like caffeine timing and room temperature</p></li><li><p><strong>Alongside it:</strong> keep up exercise, nutrition and blood pressure control, which the ACTIVE investigators are now studying alongside training</p></li><li><p><strong>If memory worries you:</strong> see a clinician, because a clinical-grade EEG or cognitive assessment beats any gadget you order yourself</p></li><li><p><strong>Watch list:</strong> HOPE results, larger tPBM trials, and bigger home sleep-stimulation studies</p></li></ul><p>None of this replaces medical care, and your doctor should know what you are doing. The honest summary is that <strong>one</strong> consumer tool has strong long-term evidence, a few have early signals, and the rest are still promises. &#127793;</p><p>So here is my question for you: if the HOPE readout lands and the numbers hold up, would you want this kind of device in your home before you need it, or only after a diagnosis?</p>]]></content:encoded></item><item><title><![CDATA[How Neurofeedback Can Deepen Your Meditation Practice (Even If You're a Skeptic)]]></title><description><![CDATA[The best-controlled evidence says brain feedback can help beginners meditate, but the headband in your drawer is probably not the device that proves it.]]></description><link>https://www.neurotechmag.com/p/how-neurofeedback-can-deepen-your</link><guid isPermaLink="false">https://www.neurotechmag.com/p/how-neurofeedback-can-deepen-your</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Fri, 23 Oct 2026 21:31:07 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!lmIF!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!lmIF!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!lmIF!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!lmIF!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!lmIF!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!lmIF!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!lmIF!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/e4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2996468,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/219651812?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!lmIF!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!lmIF!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!lmIF!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!lmIF!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe4377574-cbe2-47d1-a513-608df1fe2370_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Meditation has a feedback problem. Lift a weight and the weight tells you whether you did it right. Follow your breath and nothing tells you that you drifted off forty seconds ago. &#129496; <a href="https://en.wikipedia.org/wiki/Neurofeedback">Neurofeedback</a> tries to fix that by measuring brain activity while you sit and turning it into a sound or a graph, so you can catch your attention wandering as it happens.</p><p>I am a skeptic about most of what gets sold under this label, and the research mostly agrees with me. But &#8220;mostly&#8221; is doing real work, and the exceptions are interesting. I sort the field into three tiers: <strong>lab fMRI</strong> (real, expensive, rare), <strong>cleared clinical biofeedback</strong> (narrow claims), and <strong>consumer EEG</strong> (cheap, popular, weakly supported). Keep those apart and the rest of this article gets easier to read. &#128300;</p><h2>How brain feedback works during a sit</h2><p>The consumer version is simple. The Muse headband records from two forehead sites (AF7 and AF8) and two spots behind the ears (TP9 and TP10), with a reference at FPz. As the <a href="https://www.jmir.org/2025/1/e68204">JMIR meta-analysis</a> describes it, the app sorts your state into &#8220;Active,&#8221; &#8220;Neutral,&#8221; or &#8220;Calm&#8221; and plays something like ocean sounds back to you. The algorithm is proprietary, so nobody outside the company knows exactly what it rewards. &#127911;</p><p>The lab version is a different animal. At Yale, Kathleen Garrison and Judson Brewer used real-time fMRI to show meditators a graph of activity in the posterior cingulate cortex, a hub of the default mode network that lights up during mind-wandering. <a href="https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2013.00440/full">In their NeuroImage study</a>, meditators, but not non-meditators, deactivated that region when told to lower the graph. That is a lab demo, not a product. &#129504;</p><ul><li><p><strong>Muse (consumer wellness):</strong> four dry EEG channels with auditory feedback, and more than 500,000 users according to the JMIR paper.</p></li><li><p><strong>Neurable One and PRIME (consumer wellness):</strong> <a href="https://mezha.ua/en/news/neurable-one-brain-scanning-headpones-315749/amp/">12 EEG sensors in the earcups</a> at $499, with PRIME described by <a href="https://www.aol.com/articles/tried-neurable-brain-sensing-headphones-195555472.html">Mashable</a> as a meditation warm-up. The company&#8217;s ~40 ms reaction-time gain is a gaming result, reported by the vendor.</p></li><li><p><strong>IASIS i2 (cleared):</strong> an <a href="https://510k.innolitics.com/device/K252923">FDA 510(k) biofeedback system</a> (K252923, 21 CFR 882.5050) for relaxation and stress reduction, with at least two raw EEG channels and wired electrodes. It is prescribed, not downloaded.</p></li><li><p><strong>Real-time fMRI (research):</strong> feedback from the posterior cingulate cortex, in a scanner, one participant at a time.</p></li></ul><h2>Why the skeptic&#8217;s case is strong</h2><p>Start with the biggest summary. The JMIR paper pooled <strong>16 randomized trials</strong> (763 participants) of consumer-grade feedback with meditation, mostly using Muse. Samples ran 30 to 50 people, and <strong>no study used sham feedback</strong>. The headline result is a small drop in psychological distress (g = -0.16 under the strictest correction). There was no evidence of better cognition, mindfulness or physiological health, and no evidence that users learned to shift their brain targets. The authors flag &#8220;neurosuggestion,&#8221; a placebo effect of believing in the technology. &#9888;&#65039;</p><p>The pieces fit that picture. A <a href="https://doi.org/10.1007/s12671-020-01497-1">randomized trial of 53 novice meditators</a> found that Muse&#8217;s EEG scores did not track mindfulness gains after a month. A <a href="https://mijn.bsl.nl/eeg-neurofeedback-during-focused-attention-meditation-effects-on/18610596">crossover trial of 68 adults</a> found auditory feedback raised state mindfulness slightly (RR 1.15, with a confidence interval touching 1.00) but had a negligible effect on recovering from mind-wandering, and some people found the feedback stressful. In a different field, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5382955">Schabus and colleagues ran a double-blind sham-controlled trial</a> in 25 insomnia patients and found no advantage of real neurofeedback over placebo feedback. &#128556;</p><p>The lab literature has its own problems. A <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12315751/">systematic review of 18 fMRI and EEG studies</a> found that most lacked sham controls, that default-mode decreases may reflect general task deactivation, and that mental health benefits remain unestablished. In fairness, EEG theta modulation had the most robust support.</p><ul><li><p><strong>Sample sizes:</strong> small, usually 30 to 50.</p></li><li><p><strong>Controls:</strong> mostly meditation apps, almost never sham feedback.</p></li><li><p><strong>Duration:</strong> none of the consumer trials ran past eight weeks.</p></li><li><p><strong>Safety:</strong> adverse events were checked in only 2 of 21 studies.</p></li></ul><h2>Where the evidence gets interesting</h2><p>The strongest study I found is the one that borrows the skeptic&#8217;s own rules. In a 2025 <em>Mindfulness</em> paper, Saampras Ganesan and colleagues randomized <a href="https://www.psypost.org/high-precision-neurofeedback-accelerates-the-mental-health-benefits-of-meditation/">40 meditation novices</a> to feedback from their own posterior cingulate cortex or to <strong>yoked sham feedback</strong> recorded from someone else, all inside a 7-tesla scanner. Both groups rated the feedback as equally accurate, so blinding held. &#127919; Only the real-feedback group developed stronger negative coupling between the posterior cingulate and the dorsolateral prefrontal cortex. At home the following week, they kept their mindful awareness while the sham group&#8217;s declined, and the real-feedback group reported less emotional distress.</p><p>I like this result, and I distrust it a little. It is 40 people, two days of training and one week of follow-up. The real-feedback group also did <em>worse</em> on a breath-counting task, which the authors attribute to a clash between &#8220;letting go&#8221; and counting. And Ganesan himself says that most current wearable devices are not yet reliable enough to deliver clear benefits. A 7T scanner is not a consumer product. For the full research, funding, and trial picture behind this story, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> has you covered. &#128161;</p><p>A <a href="https://www.neuroregulation.org/article/view/23600">2026 systematic review in </a><em><a href="https://www.neuroregulation.org/article/view/23600">NeuroRegulation</a></em> of EEG neurofeedback plus meditation reaches a similar verdict: promising, but held back by non-standard protocols, small samples and limited blinding.</p><ul><li><p><strong>What worked:</strong> precise feedback tied to one clear target, plus a proper control.</p></li><li><p><strong>What did not transfer:</strong> signal quality and targeting in dry-electrode consumer hardware.</p></li><li><p><strong>What is missing:</strong> sham-controlled EEG trials at scale.</p></li></ul><h2>If you try one anyway, run it like an experiment</h2><p>I would not tell a curious person to skip these devices. Cost is modest ($100 to $200 for many of them, per the JMIR authors), and a bit of structure can help a wobbly practice. But I would treat the headband as a mirror, not a scoreboard. &#129694;</p><p>A preprint on <a href="https://arxiv.org/pdf/2605.28223">why meditation wearables fail</a> (not peer reviewed) names three traps worth keeping in mind: the device rewards the wrong proxy, you learn a trick that boosts the score without improving the practice, and the skill does not carry over when the device is off. The JMIR authors add that constant auditory feedback can pull attention away from the breath, and they suggest that open-monitoring practice or intermittent feedback might suit these tools better. That is speculation, but it is useful speculation.</p><ul><li><p><strong>Alternate weeks:</strong> four weeks with the device, four without, and note how the practice feels in each.</p></li><li><p><strong>Judge the unassisted sit:</strong> if a session without the headband feels no steadier, the score is not teaching you anything.</p></li><li><p><strong>Review after, not during:</strong> check the session summary once you finish, so the sound does not become your anchor.</p></li><li><p><strong>Ignore the number when it conflicts with your experience:</strong> the Muse trial above found the score did not track mindfulness.</p></li><li><p><strong>Remember the category:</strong> consumer EEG is sold as wellness, and <a href="https://cfg.eu/introducing-neurotech-between-wellness-and-medicine/">what makes a device medical is its intended purpose</a>, not its sensors.</p></li></ul><p>So where does that leave a skeptic? Open to the idea, hard on the evidence, and a little suspicious of any score that goes up when you do nothing differently. Which would you trust more, a number from your headband or how the third week of unassisted sits feels?</p>]]></content:encoded></item><item><title><![CDATA[5 Signs Your Company's Neurotech Wellness Perk Is Actually Working (And 3 Signs It's Not)]]></title><description><![CDATA[A prescription headset, a pair of EEG headphones and a meditation band all show up as "brain wellness," but the evidence and the privacy risk behind each one differ wildly.]]></description><link>https://www.neurotechmag.com/p/5-signs-your-companys-neurotech-wellness-490</link><guid isPermaLink="false">https://www.neurotechmag.com/p/5-signs-your-companys-neurotech-wellness-490</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Thu, 22 Oct 2026 21:29:56 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!enAT!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!enAT!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!enAT!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!enAT!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!enAT!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!enAT!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!enAT!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/b77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2190984,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/219651767?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!enAT!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!enAT!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!enAT!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!enAT!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb77b5b33-6548-4143-b490-221a4f3f2e6d_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Headbands, EEG headphones and at-home stimulation headsets are landing in benefits portals, right next to the gym discount and the meditation app. &#129504; Some of these products have real clinical evidence behind them. Others have a focus score and a nice slide deck. HR copy rarely says which is which.</p><p>This piece is a field guide. I lean on the best data I can find, I flag what is vendor-reported, and I keep three categories apart: <strong>medical</strong>, <strong>consumer wellness</strong>, and <strong>workplace monitoring</strong>. They are not interchangeable, and treating them that way is how a perk goes wrong. &#9878;&#65039; I find no trial in the sources I searched that tests a neurotech perk the way the best workplace wellness research tests ordinary ones, so some of what follows is my read on what good evidence would look like.</p><h2>Three kinds of neurotech hide behind one word</h2><p>The medical end is the easiest to pin down. <strong>Flow Neuroscience</strong> has FDA premarket approval (PMA P230024) for its <strong>FL-100</strong> headset, a prescription <a href="https://en.wikipedia.org/wiki/Transcranial_direct-current_stimulation">tDCS</a> device for adults in a current moderate-to-severe depressive episode who are not treatment-refractory. It <a href="https://hlth.com/insights/news/flow-neuroscience-launches-fda-approved-at-home-depression-treatment-in-the-us">launched in the US in September 2026</a>, backed by the 10-week, sham-controlled EMPOWER trial. &#128138; <a href="https://spectrum.ieee.org/flow-neuroscience-tdcs-depression-fda">IEEE Spectrum reports</a> that the company also sells a headset under the Halo brand, which it calls identical tDCS hardware, as a wellness device with no prescription. Same electrodes, very different claims.</p><p>The consumer end runs on <a href="https://en.wikipedia.org/wiki/Electroencephalography">EEG</a>. The Muse band uses a four-channel EEG sensor to feed meditation feedback. Neurable&#8217;s newest headphones put 12 dry EEG channels in the ear pads to estimate focus. Neither is a treatment. The third category, workplace monitoring, is where the data may travel to someone other than you. &#128064;</p><ul><li><p><strong>Medical:</strong> FL-100 is FDA-approved, prescription-only, and limited to one indication.</p></li><li><p><strong>Consumer wellness:</strong> Muse and Neurable One report scores, not diagnoses, and I find no approval for treating a condition.</p></li><li><p><strong>Workplace monitoring:</strong> fatigue and focus trackers, where the employer may see the output.</p></li><li><p><strong>Your first question:</strong> which of these three is the company actually paying for?</p></li></ul><h2>Five signs the perk is working</h2><h3>1. The claim matches the regulatory status</h3><p>If the perk is FL-100, the legitimate route is a prescription and a clinician evaluation, not a promo code. If it is an EEG band, the claims should sound like relaxation and attention training, not treatment. Mismatch is the loudest red flag in this market. &#9989;</p><p>Approval is still not the end of the argument. <a href="https://www.fastcompany.com/91552535/fda-approved-tdcs-depression-treatment">Fast Company reports</a> that a 2024 study led by Andre Brunoni found at-home use of the Flow device no better than a placebo of internet browsing, and it describes the approval trial itself as mixed. A good vendor tells you that up front. A mediocre one hopes you never read it.</p><h3>2. Nobody on the payroll can see your brain data</h3><p>This is the sign I care about most. Neural data is a new legal category, and the law is patchy. Colorado was <a href="https://news.bloomberglaw.com/privacy-and-data-security/colorado-protects-brain-wave-privacy-with-first-neurodata-law">first to cover neural data</a> in April 2024, and California added it to its sensitive-data list the same year. A California bill, AB 1883, would <a href="https://news.bloomberglaw.com/daily-labor-report/as-neurotech-goes-mainstream-states-move-to-regulate-it-at-work">restrict employer surveillance tools</a> that collect neural data, and Illinois has HB2984 pending. The Neurorights Foundation reviewed 30 consumer neurotech companies and found that nearly all appeared to have unrestricted access to users&#8217; neural data. &#128274;</p><p>So a good program shows employers aggregate numbers only, with individual data staying on your device or with a third party. Nita Farahany also points out, per the <a href="https://cdt.org/?p=105259">Center for Democracy and Technology</a>, that Colorado&#8217;s law applies only when the data is collected for identification purposes. That is a gap, not a safeguard.</p><h3>3. Someone ran a control group</h3><p>Wellness perks look great in observational data and fall apart in randomized trials. The <a href="https://www.nber.org/system/files/working_papers/w24229/w24229.pdf">Illinois Workplace Wellness Study</a> randomly assigned programs among 4,834 employees at a large employer and found no significant effects on 40 of 42 first-year outcomes, including medical spending, productivity, health behaviors and self-reported health. It also found that healthier people were the ones who signed up. &#128202;</p><p>That study did not test neurotech. I think it sets the bar anyway: if a vendor cannot describe a comparison group, the success story is probably selection.</p><ul><li><p><strong>Good sign:</strong> a waitlist or sham arm, with outcomes measured by someone outside the vendor.</p></li><li><p><strong>Weak sign:</strong> before-and-after scores from people who chose to join.</p></li><li><p><strong>Ask for:</strong> the trial registration number.</p></li></ul><h3>4. The score tracks something outside the app</h3><p>A focus score is a model output. It earns trust when it moves with behavior. Neurable reports that a US Air Force Research Lab collaboration compared its headphones against research-grade gel EEG and that the score dropped when participants were interrupted during a Stroop test, which is a reasonable design for a validation. The company&#8217;s own research page also describes a study of 43 participants over 114 hours of office work. Both are vendor-reported, so I treat them as promising, not settled. &#127911; <a href="https://spectrum.ieee.org/eeg-headphones-neurable-one">IEEE Spectrum&#8217;s reviewer</a> also said getting a good signal was sometimes a struggle, which is a fair reminder that dry sensors have limits.</p><h3>5. It targets a narrow job, like fatigue</h3><p>The best-supported workplace use is not &#8220;optimizing&#8221; everyone. It is detecting drowsiness in roles where a lapse hurts someone. <a href="https://www.verdict.co.uk/neurotechnology-brain-surveillance/">Verdict describes</a> SmartCap&#8217;s LifeBand, an EEG headband that scores fatigue from one (hyperalert) to five (involuntary sleep), and IEEE Spectrum notes that a Neurable researcher helped run a 2022 study on measuring drowsiness in truck drivers. A narrow target means a narrow, checkable claim. &#128667;</p><h2>Three signs it is not working</h2><h3>1. Managers see individual dashboards</h3><p>Some systems send concentration dips to the wearer and the manager. <a href="https://www.welcometothejungle.com/en-GB/articles/neurotech-performance-at-work">Welcome to the Jungle describes</a> earbuds that notify users and their managers through a workplace wellness app. An <a href="https://lsj.com.au/articles/neurotechnology-in-the-workplace-promise-or-peril-lawyers-grapple-with-ethical-minefield/">Australian legal forum</a> asked whether anyone can freely consent to wearing a device that is a condition of employment, and warned about discrimination against neurodivergent or older workers. A <a href="https://www.frontiersin.org/journals/human-dynamics/articles/10.3389/fhumd.2024.1473893/full">Frontiers paper on the EU position</a> notes the technology can let employers predict performance or behavior from brain data. My reaction is simple: that is surveillance with a wellness label, and people stop trusting the perk. &#128556;</p><h3>2. The proof is a tiny vendor study</h3><p>IEEE Spectrum reports a company blog claim that 67 percent of users showed a focus increase in a 20-participant experiment. That is a marketing number. Without a control group, a registered protocol or independent analysis, it cannot carry a procurement decision. &#129514;</p><h3>3. Success means sign-ups and satisfaction</h3><p>A randomized trial of 53 novice meditators, <a href="https://doi.org/10.1007/s12671-020-01497-1">published in </a><em><a href="https://doi.org/10.1007/s12671-020-01497-1">Mindfulness</a></em>, compared an app alone with the app plus a Muse headband for a month. Most people meditated three or four times a week and were happy with their device (84% in the app group, 74% in the Muse group). Yet Muse&#8217;s EEG scores did not improve, and the app-only group scored worse at follow-up. The authors conclude those scores are not a proxy for mindfulness or mental health. People liked it. That is not the same as it working. &#128201;</p><ul><li><p><strong>Red flag:</strong> satisfaction surveys are the headline result.</p></li><li><p><strong>Red flag:</strong> a dashboard score is the only outcome.</p></li><li><p><strong>Red flag:</strong> the vendor cannot say who can access raw EEG.</p></li></ul><h2>What to ask before the next renewal</h2><p>You do not need a neuroscience degree. You need five questions and the patience to ask them twice. &#128161;</p><ul><li><p>Which category is this: medical, consumer wellness, or monitoring?</p></li><li><p>Who can see individual data, and can the vendor put that in writing?</p></li><li><p>Is there a comparison group, and who measured the outcome?</p></li><li><p>What does the score correlate with outside the app?</p></li><li><p>What happens to raw EEG if the contract ends?</p></li></ul><p>If you follow this area of neurotech professionally, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> gives you the structured intelligence feed to go deeper than any single article can. For everyone else, the habit that pays off fastest is checking a vendor&#8217;s claim against its regulatory status and its trial registration before you wear anything. &#128269;</p><p>The Illinois result bothers me most because it is the best data we have and it is not about neurotech at all. So here is the question for your next benefits meeting: if the program were cancelled tomorrow, what measurable thing would change?</p>]]></content:encoded></item><item><title><![CDATA[6 Neurotech Tools That Claim to Slow Cognitive Aging - What Actually Has Evidence]]></title><description><![CDATA[Only one of them has a two-decade randomized result, and it runs on a laptop, not a headset.]]></description><link>https://www.neurotechmag.com/p/6-neurotech-tools-that-claim-to-slow-602</link><guid isPermaLink="false">https://www.neurotechmag.com/p/6-neurotech-tools-that-claim-to-slow-602</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Wed, 21 Oct 2026 21:29:32 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!HHpp!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!HHpp!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!HHpp!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!HHpp!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!HHpp!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!HHpp!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!HHpp!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2701022,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/219651715?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!HHpp!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!HHpp!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!HHpp!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!HHpp!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0642fb4b-d75d-4d4f-920d-8d9c9525c93c_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Every few months a new gadget promises to keep your brain young. Caps, headbands, light helmets, apps. &#129504; Each one comes with a study attached, and that is where the trouble starts, because &#8220;a study&#8221; can mean a 5-person case series, a company press release, or a randomized trial that ran for 20 years. Those are not the same thing, and they should not get the same headline.</p><p>I sort each tool below by how far it has actually traveled: <strong>lab demo</strong>, <strong>early clinical trial</strong>, <strong>late-stage trial</strong>, or <strong>cleared for use</strong>. One caveat first. Nearly all of the clinical data here comes from people with mild cognitive impairment or Alzheimer&#8217;s disease, which is a <em>medical</em> use. As far as I can find, none of it is cleared to slow normal aging in healthy people. &#9888;&#65039; That gap between treating a disease and keeping a healthy brain sharp is exactly the one marketing likes to blur.</p><h2>1. Speed training: the only tool with 20-year data</h2><p>The strongest result in this whole space is not a stimulator. It is the <strong>ACTIVE trial</strong>, a randomized study of more than 2,800 adults aged 65 and older, enrolled in 1998 and 1999. Participants got memory training, reasoning training, <strong>speed-of-processing training</strong>, or nothing. The training was about ten sessions over roughly six weeks. &#128200;</p><p>The <a href="https://www.uab.edu/news/research-innovation/study-shows-brain-training-can-reduce-alzheimers-and-dementia-risk-by-25-percent">20-year follow-up reported by UAB</a> found that people who did speed training and came back for booster sessions had about a <strong>25% lower risk</strong> of a dementia diagnosis. I think that is a remarkable result. I also think it needs a careful reading. &#128269;</p><ul><li><p><strong>Design:</strong> randomized, with a no-contact control group, and dementia diagnoses pulled from Medicare claims covering 1999 to 2019.</p></li><li><p><strong>The numbers:</strong> 105 of 264 people (40%) in the speed-plus-booster group were diagnosed, versus 239 of 491 (49%) in the control arm.</p></li><li><p><strong>What did not work:</strong> memory and reasoning training showed no statistically significant drop in risk, with or without boosters.</p></li><li><p><strong>The catch:</strong> the booster comparison is a subgroup of people who showed up for the extra sessions, and claims-based diagnoses are blunter than clinical exams.</p></li><li><p><strong>Stage:</strong> an updated version of the same drill is sold as the <em>Double Decision</em> exercise in the BrainHQ app, so this one is consumer software today, not a lab demo.</p></li></ul><p>The funny part is that the brain games most people actually buy look like the memory drills that did nothing. <em>Fast, adaptive visual attention</em> is the thing that moved the needle.</p><h2>2. tDCS and tACS: real signals, small trials</h2><p>Electrical stimulation through the scalp is the most hyped category here, and the evidence is the most uneven. &#128268; The best-known work comes from Robert Reinhart&#8217;s lab at Boston University. A 2022 <a href="https://doi.org/10.1038/s41593-022-01132-3">Nature Neuroscience paper</a> gave adults aged 65 to 88 <strong>20 minutes of stimulation on four consecutive days</strong>, and the memory gains lasted about a month. Low-frequency stimulation over the parietal region helped working memory, while high-frequency stimulation over the prefrontal cortex helped long-term memory. A 2019 study from the same field reported that older adults (60 to 76) matched younger adults on a working-memory task <em>while the stimulation was on</em>.</p><p>Plain tDCS looks less convincing. A <a href="https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2024.1454755">2024 meta-analysis in Frontiers in Aging Neuroscience</a> pools tDCS paired with cognitive training and finds a standardized mean difference of <strong>0.35</strong> for working memory, rising to <strong>0.72</strong> with ten or more sessions. An <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5536199">earlier analysis of 266 participants</a> found tDCS barely beat sham when added to working-memory training (g = 0.07). Both can be true, which tells you the protocol matters more than the brand name. &#129514;</p><ul><li><p><strong>Stage:</strong> lab demos and small early trials, mostly in healthy older adults.</p></li><li><p><strong>Outcome measured:</strong> performance on memory tasks, not dementia onset.</p></li><li><p><strong>Open question:</strong> how long the effect lasts past a month, and whether it transfers to daily life.</p></li><li><p><strong>If you&#8217;re building here:</strong> dose and personalization are the whole game. A single fixed montage for every older brain is probably the wrong product.</p></li></ul><h2>3. rTMS: the best Alzheimer&#8217;s data so far, from one site</h2><p><a href="https://en.wikipedia.org/wiki/Transcranial_magnetic_stimulation">Transcranial magnetic stimulation</a> has been FDA-cleared for depression since 2008, so the hardware is mature. The Alzheimer&#8217;s version is not. The candidate to watch is <strong>SinaptiStim</strong> from <strong>Sinaptica Therapeutics</strong>, which uses EEG-personalized, neuronavigated rTMS aimed at the precuneus, part of the default mode network. &#129522;</p><p>The company&#8217;s 52-week Phase 2 trial enrolled <strong>48 patients</strong> with mild-to-moderate Alzheimer&#8217;s at a single center, randomized and sham-controlled. <a href="https://www.neurologylive.com/view/sinaptica-transcranial-magnetic-stimulation-device-meets-primary-end-point-in-phase-2-trial-alzheimers">NeurologyLive reports</a> a 44% slowing on the CDR-SB scale (a 1.36-point decline versus 2.45 for sham). Co-founder Giacomo Koch of the University of Ferrara leads the science. The device has <strong>FDA Breakthrough Device Designation</strong> (2022), and a larger trial is the next step. David Knopman of the Mayo Clinic called the results strong enough to justify a bigger study, which is a fair summary and a lot more measured than the word &#8220;breakthrough&#8221; on a website. &#128527;</p><ul><li><p><strong>Stage:</strong> early clinical trial, with a Phase 3 planned. I find no readout from it yet.</p></li><li><p><strong>Sample size:</strong> 48 people, one site. Treat 44% as a hypothesis.</p></li><li><p><strong>History:</strong> an earlier rTMS device for Alzheimer&#8217;s, NeuroAD, failed its trials and was rejected by the FDA in 2018.</p></li><li><p><strong>Setting:</strong> clinic-based sessions. This is not something you strap on at home.</p></li></ul><p>Do you trust a 48-person result enough to follow the company, or do you wait for the replication? I lean toward waiting, but I keep checking.</p><h2>4. 40 Hz light and sound, and near-infrared light</h2><p>This is where the Alzheimer&#8217;s money is going. <strong>Cognito Therapeutics</strong> builds <strong>Spectris AD</strong>, a physician-prescribed, at-home system that delivers synchronized light and sound at <strong>40 Hz</strong> through glasses and headphones. The idea comes from animal work suggesting gamma-frequency stimulation can reduce amyloid plaques, and the human question is whether it slows decline. &#128161;</p><p>The early human data is the small OVERTURE feasibility study, which was not powered to show efficacy. A post hoc analysis, reported by the company, claims a 76% reduction in cognitive decline over six months. I would not lean on a post hoc slice of a small study. The real test is <strong>HOPE</strong> (NCT05637801): a sham-controlled, late-stage trial with <strong>670 patients</strong> at more than 60 U.S. sites, MMSE scores of 15 to 28, 12 months of daily home use, and a composite primary endpoint of ADCS-ADL and MMSE. Cognito <a href="https://hlth.com/insights/news/cognito-therapeutics-raises-105m-series-c-led-by-morningside-ventures-to-advance-spectris-platform-for-alzheimer-s-2026-03-06">closed a $105 million Series C</a> in March 2026 to support the readout and regulatory filing, and topline data was promised before the end of 2026. I find no published topline as of today. For the full research, funding, and trial picture behind this story, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> has you covered. &#128176;</p><p>Near-infrared <strong>photobiomodulation</strong> sits a step behind. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5568598">2017 case series</a> used 810 nm light pulsed at 10 Hz in <strong>five patients</strong> with dementia and reported gains on MMSE and ADAS-cog, but the authors themselves call for larger controlled trials. A <a href="https://www.medrxiv.org/content/10.1101/2025.08.19.25333989v2">pilot sham-controlled trial in mild cognitive impairment</a> (NCT05563298) is posted as a preprint, so it is not peer reviewed yet. &#128262;</p><ul><li><p><strong>Spectris AD:</strong> late-stage trial, investigational, with Breakthrough Device Designation and no reported ARIA events.</p></li><li><p><strong>Photobiomodulation:</strong> early clinical trials in dementia and MCI, with a positive pooled signal across 13 mostly small studies.</p></li><li><p><strong>Consumer note:</strong> near-infrared helmets are sold as wellness gear. That is a retail fact, not a clinical one.</p></li></ul><h2>5. Neurofeedback, and what would change my mind</h2><p>The sixth tool is <strong>EEG neurofeedback</strong>, where you watch your own brain activity and learn to shift it. The results are the most mixed of the six. &#127919; A <a href="https://www.frontiersin.org/articles/10.3389/fnbeh.2018.00321/text">small placebo-controlled study of 17 older adults</a> found that sensorimotor rhythm training improved visual working memory. But a <a href="https://repub.eur.nl/pub/68818">double-blind study of 20 older adults</a> found that gamma and beta training raised brain activity within sessions with no effect on cognition, and a <a href="https://uvadoc.uva.es/handle/10324/83930">recent randomized trial of motor-imagery neurofeedback</a> saw no cognitive gains beyond classical stimulation. Older brains produce noisier signals, and protocols built on young adults do not always transfer. &#128201;</p><ul><li><p><strong>Stage:</strong> early trials and pilots, with consumer EEG headbands already on the market.</p></li><li><p><strong>Pattern:</strong> people learn to move the signal, but the cognitive payoff is inconsistent.</p></li><li><p><strong>Bottom line:</strong> promising enough to study, not strong enough to buy on faith.</p></li></ul><p>Here is what would change my mind. A clean HOPE readout would make 40 Hz stimulation the first at-home neurotech with late-stage evidence in Alzheimer&#8217;s. A multi-site rTMS replication would move magnetic stimulation from interesting to credible. A properly blinded photobiomodulation trial with hundreds of people would settle a decade of case reports. Until then, the only thing with two decades of data is a speed drill you can run on a laptop. Which of these would you bet on if the next readout lands in your favor?</p>]]></content:encoded></item><item><title><![CDATA[7 Neurotech Gifts for the Person Who Has Everything (Ranked by Actual Usefulness)]]></title><description><![CDATA[Some of these read your brain, one zaps it, and exactly one needs a prescription, so the ranking depends on what the evidence supports and not on the packaging.]]></description><link>https://www.neurotechmag.com/p/7-neurotech-gifts-for-the-person</link><guid isPermaLink="false">https://www.neurotechmag.com/p/7-neurotech-gifts-for-the-person</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Fri, 16 Oct 2026 18:02:14 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!CbTR!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!CbTR!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!CbTR!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!CbTR!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!CbTR!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!CbTR!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!CbTR!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/e1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2438517,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/219308943?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!CbTR!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!CbTR!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!CbTR!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!CbTR!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe1440325-387f-4747-b4bc-1ce68e6e87de_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Gift guides love to blur categories. A headband that logs alpha waves gets listed next to a headset that delivers current to the scalp, and both get the same five stars. I think that is a disservice, so this list sorts by one question: what does the device actually do for a person, and how good is the proof? &#129504;</p><p>Everything below is a <strong>consumer or wellness product</strong>, with one <strong>medical exception</strong> I&#8217;ll flag when we get there. None of it is military hardware, and none of it is an implant. Prices move around and some figures come from company materials, so I&#8217;ll say so each time. Expect a lot of <em>dry electrodes</em>, a fair amount of <em>sham-controlled</em> caveats, and at least one gift you can&#8217;t wrap. &#127873;</p><h2>Ranks 1 to 3: the headsets that give you data you can use</h2><p><strong>1. Muse S Athena.</strong> It is the most mature product on this list, and it is the only one I&#8217;d hand to a total beginner. According to <a href="https://choosemuse.com/blogs/news/top-brain-training-devices-2026">Muse&#8217;s own comparison of brain training devices</a>, the Athena pairs <strong>4 EEG channels</strong> with <strong>fNIRS</strong>, which tracks blood flow in the prefrontal cortex. That claim comes from the maker, so weigh it accordingly. Independent reviewers are more measured. <a href="https://medicalfuturist.com/the-muse-headband-review-meditation-2-0">The Medical Futurist&#8217;s 2026 review</a> calls the evidence for consumer devices used outside a lab <em>mixed</em>, even as it praises the redesign. &#128200;</p><p><strong>2. Neurosity Crown.</strong> This is the one for the friend who writes code. The Crown has <strong>8 EEG channels</strong> and offers developer access through an SDK, a feature Muse&#8217;s comparison also notes for Neurosity. Buy it if your recipient will build something with the raw signal. Skip it if they want a guided meditation app. &#9889;</p><p><strong>3. OpenBCI Ganglion or Cyton.</strong> <a href="https://docs.openbci.com/FAQ/HowProductsGoTogether">OpenBCI&#8217;s documentation</a> lists the <strong>Ganglion at 4 channels and 200 Hz</strong>, the <strong>Cyton at 8 channels and 250 Hz</strong>, and the Cyton with the Daisy module at 16 channels and 125 Hz. It is open hardware for tinkerers, not a wellness gadget. Older roundups put the boards at roughly $99 and $499, but check current pricing.</p><p>What these three share:</p><ul><li><p>They measure brain activity but do not stimulate it</p></li><li><p>They are <strong>wellness or research tools</strong>, not diagnostic devices</p></li><li><p>Signal quality from dry electrodes is <em>good enough for trends</em>, not for clinical readings</p></li><li><p>The software, not the sensor, decides whether the gift gets used past week two</p></li></ul><p>Which of your friends would still be using one in March? Be honest. &#128300;</p><h2>Ranks 4 to 6: nicer ideas with thinner evidence</h2><p><strong>4. Neurable x Master &amp; Dynamic MW75 Neuro.</strong> These are headphones with <strong>12 channels of dry fabric EEG</strong> in the ear pads, and <a href="https://www.masterdynamic.com/products/mw75-neuro">Master &amp; Dynamic&#8217;s product page</a> sells them at <strong>$699</strong> as a focus and burnout tracker. <a href="https://www.gearpatrol.com/audio/mw75-neuro-headphones/">Gear Patrol</a> reports that processing happens on the device, which I like from a privacy angle, and says plainly that the sensors cannot tell what you are thinking. They are a wellness product with nice drivers. If your recipient already wants premium noise-canceling headphones, the EEG is a bonus. If not, it&#8217;s an expensive experiment. &#127911;</p><p><strong>5. Somnee Smart Sleep Headband.</strong> This one is a <strong>closed-loop stimulation</strong> device. It reads EEG and delivers <strong>tACS</strong>, a weak alternating current, aimed at sleep onset. Preqin lists the price at <strong>$299</strong>. The company reported a <strong>1,500-night home pilot</strong> in which users fell asleep in about half the time, according to <a href="https://hitconsultant.net/?p=66185">its launch announcement</a>, and that is a company study, not an independent trial. It is positioned as a consumer wellness device, and I found no FDA clearance. Read the return and membership terms before buying. &#128564;</p><p><strong>6. Mendi.</strong> A forehead band using <strong>fNIRS</strong> neurofeedback for around <strong>$299</strong>. A <a href="https://www.cordis.europa.eu/article/id/422065-bringing-advanced-neurofeedback-brain-training-to-consumers">CORDIS summary of the EU-backed project</a> reports a <strong>0.81 group-level correlation</strong> with a laboratory fNIRS device, which says the sensor works. It does not say that training with it improves your focus. <a href="https://www.mindbodygreen.com/articles/mendi-headset-review-can-you-train-your-brain">MindBodyGreen&#8217;s review</a> notes there are no large-scale clinical trials and no FDA clearance. &#129514;</p><p>Ranking logic for this tier:</p><ul><li><p><strong>Measurement validity</strong> is better established than <strong>benefit</strong></p></li><li><p>Company studies are small and self-published</p></li><li><p><em>Wellness positioning</em> keeps all three outside FDA review</p></li><li><p>Price tracks marketing more than evidence</p></li></ul><h2>Rank 7: the one you can&#8217;t wrap</h2><p><strong>7. Flow FL-100.</strong> This is the most important device on the list and the worst gift. It is a headset delivering <strong>tDCS</strong> for <strong>major depressive disorder</strong>, authorized through <strong>FDA Premarket Approval (PMA P230024)</strong> for adults with a current moderate-to-severe episode who are not treatment-refractory. It needs a prescription. According to <a href="https://hlth.com/insights/news/flow-neuroscience-launches-fda-approved-at-home-depression-treatment-in-the-us">HLTH&#8217;s coverage of the US launch</a>, it went on sale in the US on September 9, 2026. &#128138;</p><p>The evidence is real but contested. The approval rests on the 10-week, sham-controlled <strong>EMPOWER trial</strong>, <strong>174 participants</strong>, published in <em>Nature Medicine</em>. One summary at <a href="https://alert.psychnews.org/fda-approves-at-home-brain-stimulation-device">Psychiatric News</a> reports <strong>57% remission versus 29% on sham</strong>, and Reuters expected a price of <strong>$500 to $800</strong>. Yet <a href="https://scientificamerican.com/article/u-s-approves-first-device-to-treat-depression-with-brain-stimulation-at-home">Scientific American notes</a> that a 2023 <em>Lancet</em> trial found tDCS no better than placebo. The FDA itself flagged limits in how to read the rating-scale gains. I think the honest takeaway is this: <strong>a cleared medical device with a modest, argued-over effect</strong>. <a href="https://spectrum.ieee.org/flow-neuroscience-tdcs-depression-fda">IEEE Spectrum</a> adds that Flow&#8217;s sister brand Halo sells similar hardware as a non-prescription wellness product, which is exactly where the medical and consumer lines get slippery.</p><p>Don&#8217;t give this to anyone as a surprise. If someone you love has depression, the useful gift is a conversation about asking their clinician. &#129658;</p><h2>Before you buy: who owns the brain data</h2><p>Every gift above produces <strong>neural data</strong>, and the legal protection for it is patchy. <a href="https://www.kunc.org/news/2025-07-26/states-pass-privacy-laws-to-protect-brain-data-collected-by-devices">Colorado, California and Montana</a> have passed laws covering brain data from consumer devices, and Colorado requires initial express consent to collect or use it. A Neurorights Foundation report, covered by <a href="https://news.bloomberglaw.com/privacy-and-data-security/colorado-protects-brain-wave-privacy-with-first-neurodata-law">Bloomberg Law</a>, found that nearly all of the 30 consumer neurotech companies it reviewed appeared to have access to users&#8217; neural data without meaningful limits. If you live elsewhere, you may have none of those protections, and since developments like this rarely happen in isolation, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> tracks the research, funding, and trials that surround them. &#128274;</p><p>A short checklist before checkout:</p><ul><li><p>Read the privacy policy for the words <strong>&#8220;neural data&#8221;</strong> and &#8220;sell&#8221;</p></li><li><p>Check whether raw data <strong>leaves the device</strong></p></li><li><p>Find out if the <strong>app works without a subscription</strong></p></li><li><p>Confirm the return window starts at <strong>delivery</strong>, not order date</p></li></ul><p>My own ranking: Muse first, Flow last as a gift but first as science. What would yours look like, and which of these would you actually wear every night? &#128640;</p>]]></content:encoded></item><item><title><![CDATA[5 Signs Your Company's Neurotech Wellness Perk Is Actually Working (And 3 Signs It's Not)]]></title><description><![CDATA[A headband in the benefits portal is a product choice, a data policy, and a measurement problem at once, and most employers only handled the first.]]></description><link>https://www.neurotechmag.com/p/5-signs-your-companys-neurotech-wellness</link><guid isPermaLink="false">https://www.neurotechmag.com/p/5-signs-your-companys-neurotech-wellness</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Thu, 15 Oct 2026 18:01:53 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!ZJ3d!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!ZJ3d!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!ZJ3d!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!ZJ3d!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!ZJ3d!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!ZJ3d!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!ZJ3d!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2162427,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/219308849?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!ZJ3d!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!ZJ3d!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!ZJ3d!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!ZJ3d!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9bc36c2d-673c-4f3c-b734-3894d10a5634_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Somewhere in a benefits portal near you, a <strong>neurotech wellness perk</strong> sits next to the gym discount and the meditation app &#129504;. It is a dry-electrode EEG headband, a pair of EEG earbuds, or a sleep wearable. Someone in HR approved it after a slide deck full of &#8220;focus score&#8221; charts.</p><p>Here is the catch. This is a <em>consumer wellness</em> product, not a medical one. There are no implants, no IDE trial phase, and no FDA clearance for any condition. That gap decides what the device can honestly tell you, and it decides whether your program works or just runs &#9889;. Below are five signs it works and three signs it does not. Keep a tally as you read.</p><h2>What you are actually buying</h2><p>Start with the hardware, because the specs are modest. The Muse 2 is a <strong>four-channel dry-electrode</strong> headband. A <a href="https://doaj.org/article/9b45e126560145f79cc4932dddc63d78">2024 study in </a><em><a href="https://doaj.org/article/9b45e126560145f79cc4932dddc63d78">Sensors</a></em> with 37 participants found it can capture the N400 effect (a brain response to unexpected words) over a right frontal electrode. That is a real result &#128300;. It is also a seated lab task, which is a long way from an open-plan office. An <a href="https://ideas.repec.org/h/spr/seschp/978-3-319-74295-3_8.html">earlier study of lecture audiences</a> called the usefulness of consumer headbands like Muse &#8220;extremely limited&#8221; outside laboratory conditions.</p><p>The sleep side is similar. Elemind&#8217;s headband uses <strong>three frontal EEG electrodes</strong> and bone-conduction audio to deliver pink noise timed to alpha waves. The company reports that <strong>76% of trial participants</strong> fell asleep faster, by an average of 48%. <a href="https://sleepreviewmag.com/?p=415240">Sleep Review</a> notes that the supporting study is small, the cross-validation against a Nox A1S sleep system is unpublished, and the device is not FDA-cleared to treat any sleep disorder.</p><p>Sort what you have into the right bucket:</p><ul><li><p><strong>Commercially available, general wellness:</strong> Muse-style EEG headbands and Elemind&#8217;s sleep headband. Nothing here is cleared to diagnose or treat.</p></li><li><p><strong>Lab validation on narrow tasks:</strong> the Muse N400 work. It is a paper result, not a workplace result.</p></li><li><p><strong>Company-reported trial data:</strong> Elemind&#8217;s 76% figure. Treat it as a vendor claim until independent replication shows up.</p></li><li><p><strong>Medical BCI:</strong> Neuralink and similar implant trials. This is a different regulatory universe, and it is not what your employees are wearing &#128640;.</p></li></ul><p>The FDA reinforced the wellness line in its <a href="https://hlc.com/en/publications/fda-town-hall-sheds-new-light-on-updated-general-wellness-policy">January 2026 update to the general wellness guidance</a>. Labeling should not suggest a product is medical or clinical grade. Pull up your vendor&#8217;s materials and look for that phrase. If you find it, you have already learned something.</p><h2>Five signs it is working</h2><p>A working program is boring in the right places. Here is what I would look for &#128200;.</p><ul><li><p><strong>The claims stay in the wellness lane.</strong> The vendor says &#8220;sleep onset&#8221; or &#8220;relaxation,&#8221; not &#8220;diagnose burnout.&#8221; HR repeats the same language.</p></li><li><p><strong>Opt-in is real.</strong> Employees can decline, or quit after week two, with zero consequence. Nobody tracks who didn&#8217;t join.</p></li><li><p><strong>The employer sees aggregates, never individuals.</strong> There is no per-person dashboard. Your vendor can say in writing where raw EEG waveforms are stored and who can read them.</p></li><li><p><strong>Outcomes match what the sensor can support.</strong> Self-reported time to fall asleep is something a sleep headband can plausibly move. A company-wide &#8220;focus index&#8221; built from four forehead electrodes is a much weaker claim.</p></li><li><p><strong>Someone built a comparison group.</strong> Even a rough one, like one office with the perk and one without, beats a before-and-after chart.</p></li></ul><p>That last point deserves a detour. The <a href="https://www.nber.org/programs-projects/projects-and-centers/workplace-wellness/illinois-workplace-wellness-results">Illinois Workplace Wellness Study</a> randomized <strong>4,834 employees</strong> over two years. The comprehensive program had <em>no significant effect</em> on measured physical health outcomes, diagnoses, or health care use. It did raise the share of employees who reported having a primary care physician. That trial involved screenings and health risk assessments, not EEG headbands, so it is not a verdict on neurotech. It is a warning about how easily a wellness program looks good when the enthusiastic people sign up first.</p><p>So how many of the five can you honestly check off today?</p><h2>Three signs it is not</h2><p>The failure modes are just as specific, and two of them carry legal risk &#128274;.</p><ul><li><p><strong>Managers can see individual scores.</strong> Per-person focus, stress, or fatigue numbers are the clearest red flag. Emotiv&#8217;s COO told Bloomberg Government the company has had interest in workplace research but <a href="https://news.bgov.com/daily-labor-report/as-neurotech-goes-mainstream-states-move-to-regulate-it-at-work">does not offer an off-the-shelf product for employers to monitor or evaluate employees</a>. California&#8217;s AB 1883 would restrict employer use of surveillance tools that collect neural data, and Illinois has a bill pending that would ban neurotech in employment decisions. Check where both stand before you renew.</p></li><li><p><strong>The marketing drifts toward medicine.</strong> If the pitch moves from &#8220;sleep better&#8221; to &#8220;reduces anxiety disorders,&#8221; the product is leaving general wellness territory without the evidence a cleared device would need. <em>That&#8217;s a vendor problem that becomes your problem.</em></p></li><li><p><strong>Participation is the only metric.</strong> High sign-up numbers can mean the perk works, or they can mean the same self-selected, already-healthy group showed up. The Illinois researchers found their participants had <em>lower</em> baseline medical spending than those who skipped the program.</p></li></ul><p>The privacy angle makes all three worse. The FDA says it does not plan to evaluate general wellness products for medical device cybersecurity, and <a href="https://spectrum.ieee.org/fda-medical-device-rules">IEEE Spectrum</a> points out that many wellness device makers fall outside HIPAA. Your headband data may have fewer protections than your dentist&#8217;s billing record &#128556;.</p><h2>What to do before the next renewal</h2><p>State law is where employers get surprised. Colorado&#8217;s HB 24-1058 treats neural data as sensitive and requires opt-in consent. <a href="https://www.bakerlaw.com/insights/colorado-and-california-get-ahead-of-neural-data-regulation">BakerHostetler notes</a> an important wrinkle: California&#8217;s CCPA covers employee personal information, while the Colorado Privacy Act does not. Definitions of neural data also differ by state, so a multi-state employer faces a patchwork, not a single rule. Every paper, funding round, and trial update we report on ends up summarized and searchable in <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a>, which is a decent place to watch this moving target &#128161;.</p><p>Before you sign again, run this short checklist:</p><ul><li><p>Ask the vendor for the <strong>independent validation studies</strong>, not the press release.</p></li><li><p>Get a written answer on <strong>where raw neural data lives</strong> and who can access it.</p></li><li><p>Pick <strong>one outcome</strong> the device can plausibly move, and measure it against a comparison group.</p></li><li><p>Review every HR slide and email for <strong>medical-sounding claims</strong>.</p></li><li><p>Confirm which <strong>state neural data laws</strong> apply to your workforce.</p></li></ul><p>If your program passes four of those five, you are ahead of most employers I can imagine. If it passes two, you probably have a headband subscription, not a wellness program. Which one does your company have?</p>]]></content:encoded></item><item><title><![CDATA[6 Neurotech Tools That Claim to Slow Cognitive Aging - What Actually Has Evidence]]></title><description><![CDATA[Headsets, magnets and implants all promise to protect memory, but the evidence runs from a four-day lab study to a 670-person trial that has not reported yet.]]></description><link>https://www.neurotechmag.com/p/6-neurotech-tools-that-claim-to-slow</link><guid isPermaLink="false">https://www.neurotechmag.com/p/6-neurotech-tools-that-claim-to-slow</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Wed, 14 Oct 2026 18:00:47 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!gd68!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!gd68!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!gd68!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!gd68!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!gd68!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!gd68!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!gd68!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2532515,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/219308771?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!gd68!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!gd68!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!gd68!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!gd68!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4915be90-5768-4bc2-a1a7-938a91a7cf52_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Search for ways to slow cognitive aging and you land on a pile of devices, each with a confident website. The evidence behind them is wildly uneven. Some of it is a short experiment in a university lab. Some of it is a <strong>sham-controlled trial with 670 patients</strong> that has not read out. A little of it is a surgical implant whose latest results I cannot find.</p><p>Two things to keep straight before we start. First, the <strong>medical and consumer</strong> lines matter here. A single-channel consumer EEG headset and a physician-prescribed device face very different evidence bars, and none of the six tools below is a defense application. Second, most of the late-stage work targets <strong>Alzheimer&#8217;s disease</strong>, not the ordinary memory slippage of a healthy 70-year-old. Those are different problems, and I think the marketing blurs them more than it should.</p><h2>Lab results: tACS, tDCS and neurofeedback</h2><p><strong>1. High-definition tACS.</strong> The strongest lab result in older adults comes from Robert Reinhart&#8217;s group at Boston University. In <a href="https://doi.org/10.1038/s41593-022-01132-3">a 2022 Nature Neuroscience paper</a>, Shrey Grover and colleagues give healthy adults aged 65 to 88 <em>20 minutes of weak alternating current</em> a day for four days. Low-frequency stimulation over the parietal region improves <strong>working memory</strong>. High-frequency stimulation over the prefrontal cortex improves <strong>long-term memory</strong>. Both gains are still visible a month later. &#129504; The catch is size. Oxford&#8217;s Masud Husain points out that the gain is roughly three to four extra words from a list of 20, and participants receive stimulation while they do the memory task. Stage: <strong>academic randomized study, no commercial product</strong>.</p><p><strong>2. tDCS.</strong> This is the cheapest and most widely copied approach, and the evidence is the least tidy. A <a href="https://doi.org/10.1186/s13195-025-01677-y">2025 meta-analysis in Alzheimer&#8217;s Research &amp; Therapy</a> finds that tDCS raises MMSE scores in older adults with cognitive impairment, but it does not significantly improve memory or executive function. &#9889; In healthy older adults, a separate review pools <strong>13 trials and 647 participants</strong>, mostly at 1 to 2 mA over the prefrontal cortex, and calls the results promising. Any consumer headset built on this approach inherits that mixed base.</p><p><strong>3. Consumer EEG neurofeedback.</strong> A <a href="https://games.jmir.org/2021/2/e26872">2021 pilot study in Thailand</a> has older adults play brain games on a <strong>single-channel consumer EEG headset</strong> for 20 sessions. Resting upper alpha activity improves (P=.04). But the design is pre-post, with no control group, so a practice effect is hard to rule out. &#127918; A <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11737249/">systematic review of EEG-based BCI training in older people</a> reaches a similar verdict: promising, thin, and short on well-designed trials.</p><p>Where each one stands:</p><ul><li><p><strong>HD-tACS:</strong> sham-controlled lab study, effect at one month, no product</p></li><li><p><strong>tDCS:</strong> many small trials, mixed outcomes, no cleared device for this use that I can find</p></li><li><p><strong>EEG neurofeedback:</strong> pilot with no control group, consumer hardware</p></li></ul><p>If a headset maker says its product &#8220;builds on&#8221; research like this, ask which of those three rows it actually sits in. Which row would you bet on?</p><h2>Late-stage devices: gamma light and sound, and precuneus TMS</h2><p><strong>4. Cognito Therapeutics Spectris.</strong> The system delivers synchronized <strong>40 Hz light and sound</strong> through glasses and headphones, one hour a day at home. The idea traces back to MIT&#8217;s Li-Huei Tsai and Ed Boyden. &#128640; In the OVERTURE feasibility study, patients with mild to moderate Alzheimer&#8217;s show less white matter loss than sham. A later MRI comparison against matched ADNI controls reports brain volume of <strong>+0.58% versus -0.91%</strong>. That comparison uses external controls, though, and OVERTURE was not powered to show efficacy. The real test is the <a href="https://clinicaltrials.gov/study/NCT05637801">HOPE trial</a>: <strong>670 participants</strong>, about 70 US sites, sham-controlled, with a primary endpoint combining daily function and cognition. Cognito closed a <a href="https://hlth.com/insights/news/cognito-therapeutics-raises-105m-series-c-led-by-morningside-ventures-to-advance-spectris-platform-for-alzheimer-s-2026-03-06">$105 million Series C in March 2026</a> and expects topline data before the end of the year. I find no results yet. One more caution: sensory stimulation has not been shown to lower amyloid or tau in people, so the mechanism is still an open question.</p><p><strong>5. Sinaptica SinaptiStim.</strong> This is personalized rTMS aimed at the <strong>precuneus</strong>, a hub of the default mode network, calibrated with concurrent TMS and 64-channel EEG plus MRI neuronavigation. Co-founders Emiliano Santarnecchi and Giacomo Koch run the science. &#128200; The <a href="https://www.biospace.com/press-releases/positive-data-published-in-alzheimers-research-therapy-from-12-month-phase-2-study-in-alzheimers-using-personalized-neuromodulation-therapy-trial-met-all-primary-and-key-secondary-endpoints">52-week Phase 2 results</a> cover <strong>32 patients</strong> with mild to moderate Alzheimer&#8217;s, who score 1.09 points better on the CDR-SB than sham. The FDA granted Breakthrough Device Designation in 2022, and the system is investigational only. The trial that would support clearance keeps slipping on the calendar, and I find no confirmation that it has started. An earlier rTMS device, NeuroAD, failed its trials and was rejected by the FDA in 2018, which is a useful reminder that small positive trials do not always replicate.</p><p>What to watch:</p><ul><li><p><strong>HOPE topline:</strong> Cognito says before the end of 2026</p></li><li><p><strong>HOPE endpoint:</strong> daily function plus cognition, a stricter bar than a biomarker</p></li><li><p><strong>Sinaptica trial start:</strong> not confirmed in anything I can find</p></li><li><p><strong>Amyloid and tau:</strong> no human reduction from sensory stimulation so far</p></li></ul><p>Would a clean HOPE result change how you think about non-drug Alzheimer&#8217;s care? I think it would, and quickly.</p><h2>Deep brain stimulation: the invasive bet</h2><p><strong>6. Fornix DBS.</strong> Functional Neuromodulation implants electrodes in the <strong>fornix</strong>, the fiber bundle that carries output from the hippocampus. &#127973; The Phase 2 ADvance trial enrolls <strong>42 patients</strong> with mild Alzheimer&#8217;s in an on-versus-off design, and the age analysis finds the most benefit in patients over 65. That result drives the follow-up, <a href="https://clinicaltrials.gov/study/NCT03622905">ADvance II</a>, a 12-month double-blind study of up to 210 people aged 65 or older. It uses Boston Scientific&#8217;s Vercise directional system and carries FDA Breakthrough designation. The trial record lists completion in February 2024. I cannot find published efficacy results, which is odd for a study that finished this long ago. &#128295;</p><p>The facts that matter:</p><ul><li><p><strong>Population:</strong> mild probable Alzheimer&#8217;s, age 65 and older</p></li><li><p><strong>Design:</strong> randomized, double-blind, stimulation on versus off</p></li><li><p><strong>Hardware:</strong> Boston Scientific Vercise directional DBS</p></li><li><p><strong>Status:</strong> completed per the trial record, no published efficacy data that I can find</p></li></ul><p>This is a <em>surgical</em> option for diagnosed disease. It is not a wellness product, and nobody should read it as a way to slow ordinary aging. &#9888;&#65039;</p><h2>How to read the claims</h2><p>A <a href="https://doi.org/10.3389/fnins.2026.1890235">2026 network meta-analysis in Frontiers in Neuroscience</a> finds domain-specific benefits from neuromodulation in Alzheimer&#8217;s, with no single technique clearly ahead. That matches what the six tools above suggest. &#128300; Every approach has a signal, and none has a finished case. Every paper, funding round, and trial update we report on ends up summarized and searchable in <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a>, which helps if you want to track HOPE and the others as they move.</p><p>If you are evaluating a device or building in this space, run each claim through four questions:</p><ul><li><p>Is the control group sham-stimulated, or just untreated?</p></li><li><p>Is the population healthy older adults or diagnosed Alzheimer&#8217;s?</p></li><li><p>Is the primary endpoint a clinical scale or a biomarker?</p></li><li><p>Is there FDA clearance for this specific use? For slowing cognitive aging, I find none among the six.</p></li></ul><p>Most pitches fail at least two of those. &#128201; The ones that pass all four will probably be the ones with a pivotal-grade readout behind them, and only Cognito is close to one this year.</p><p>Which of these six would you most want to see a clean sham-controlled result from, and what would count as clean enough for you?</p>]]></content:encoded></item><item><title><![CDATA[5 Red Flags That Separate Real Neurotech Startups From Vaporware]]></title><description><![CDATA[A demo video is not a trial, a designation is not an approval, and "wellness" is not a get-out-of-evidence card: here is how to tell what is shipping from what is being pitched.]]></description><link>https://www.neurotechmag.com/p/5-red-flags-that-separate-real-neurotech</link><guid isPermaLink="false">https://www.neurotechmag.com/p/5-red-flags-that-separate-real-neurotech</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Fri, 09 Oct 2026 05:04:39 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!F0LZ!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!F0LZ!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!F0LZ!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!F0LZ!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!F0LZ!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!F0LZ!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!F0LZ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2289437,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/217491908?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!F0LZ!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!F0LZ!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!F0LZ!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!F0LZ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3fcaff6e-8d53-4337-8014-314b767ef192_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Neurotech has a vaporware problem for a simple reason: the real thing is spectacular. &#129504; Paralyzed people move cursors with their thoughts, and that is a matter of record. So a startup with a sleek render and a founder who talks fast can borrow that credibility without owning any of the proof.</p><p>This is a checklist for readers, investors and journalists. Every red flag below is a <em>signal</em>, not a verdict. A company can trip one for innocent reasons, and a real one can be early, quiet and awkward on stage. I use named companies only as reference points for what the paper trail looks like when it exists, and where I cite an enforcement action, I report what the agency alleged and nothing more. The test throughout is the one this publication cares about: does the story separate a <strong>lab demo</strong>, an <strong>early clinical trial</strong>, a <strong>cleared product</strong>, and something <strong>years away</strong>? <em>How many pitches you have seen this year do that on slide one?</em></p><h2>Red flag 1: a designation gets sold as an approval</h2><p>Regulatory vocabulary is a minefield, and some founders wade in on purpose. The one to know is <strong>Breakthrough Device designation</strong>. The FDA states that it is <a href="https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program">neither an approval nor a clearance</a>. It is a program status, granted before a marketing submission, that buys prioritized review and more frequent talks with the agency. The device still has to clear the <em>same</em> safety and effectiveness bar. &#129534;</p><p>Real companies hold designations and say so carefully. <a href="https://www.basenor.com/blogs/news/neuralink-reaches-26th-patient-in-ongoing-brain-computer-interface-trials">Neuralink&#8217;s implant</a> has Breakthrough designation for speech restoration and its Blindsight project, and it has 26 patients as of June 2026, in trials across the US, UAE, UK and Canada. None of that is a marketing authorization. &#128679; Synchron holds a designation from August 2020 and, per <a href="https://theroboticsmedia.com/article/synchron-stentrode-pivotal-trial-2026-fda-pma-bci-200-million-series-d">The Robotics Media</a>, is preparing the first trial meant to support a PMA for a permanently implanted BCI.</p><ul><li><p><strong>Green flag:</strong> the deck names the pathway (IDE, De Novo, 510(k), PMA) and the stage in the same sentence</p></li><li><p><strong>Yellow flag:</strong> &#8220;FDA-backed,&#8221; &#8220;FDA-recognized&#8221; or &#8220;FDA-fast-tracked&#8221; with no pathway named</p></li><li><p><strong>Red flag:</strong> a designation, a meeting or a registration presented as if it were authorization</p></li></ul><p>Even <em>real</em> clearances have limits. Precision Neuroscience <a href="https://www.globenewswire.com/news-release/2025/04/17/3063418/0/en/Precision-Neuroscience-Receives-FDA-Clearance-for-High-Resolution-Cortical-Electrode-Array.html">announced 510(k) clearance</a> in April 2025 for its cortical electrode array, for recording, monitoring and stimulation of brain-surface activity, with implants of <strong>up to 30 days</strong>. That is a real authorization for a temporary, removable device. &#9989; It is not a permanent home BCI, and a headline that blurs those two is doing the blurring on purpose.</p><h2>Red flag 2: no trial anyone can look up</h2><p>Real neurotech leaves a paper trail, because regulators, ethics boards and hospitals demand one. A company with human data should be able to tell you the design, the number of participants, the endpoints, and where to find the registry entry on <a href="https://clinicaltrials.gov/">ClinicalTrials.gov</a>. If the evidence is a video of one impressive session, it is a demo. Demos are fine. Calling them a <em>trial</em> is the problem. &#127909;</p><p>Look at what a modest, honest result looks like. Synchron&#8217;s COMMAND early feasibility study enrolled <strong>six patients</strong> and, as of September 30, 2024, all six <a href="https://theroboticsmedia.com/article/synchron-stentrode-pivotal-trial-2026-fda-pma-bci-200-million-series-d">met the primary safety endpoint</a> over 12 months with no serious adverse events involving the brain or vasculature. Six people is small. &#128269; It is also specific, checkable and about <em>safety</em>, which is what an early study is supposed to be about.</p><ul><li><p><strong>Ask for:</strong> sample size, control condition, primary endpoint, and follow-up length</p></li><li><p><strong>Watch for:</strong> &#8220;thousands of users&#8221; standing in for a trial, or self-reported surveys described as a study</p></li><li><p><strong>Discount:</strong> results that appear only in the company&#8217;s own press release, until a peer-reviewed paper exists</p></li></ul><p>Funding is not evidence either, but it is context worth having. Synchron announced a <strong>$200 million</strong> Series D in November 2025, and that money follows a trial record instead of replacing one. If you want to see who is funding what, and how a startup&#8217;s papers, rounds and trials line up, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> members can track every paper, funding round, and trial connected to developments like these, summarized and searchable. &#128200;</p><h2>Red flag 3: &#8220;wellness&#8221; on the box, medicine in the marketing</h2><p>In the US, a company can sell an EEG headband, a focus tracker or a sleep earbud without FDA review if it stays inside the <strong>general wellness</strong> lane, which <a href="https://www.neurotechmag.com/p/5-neurotech-myths-that-are-scaring">NeurotechMag&#8217;s myths piece</a> explains well. The January 2026 guidance, as <a href="https://natlawreview.com/article/fdas-2026-general-wellness-policy-and-what-it-means-manufacturers-wearable-devices">summarized by the National Law Review</a>, keeps claims about stress, sleep and fitness inside the lane. Claims to cure, mitigate, prevent or treat a disease, &#8220;medical grade&#8221; language, and prompts to change treatment fall outside it. &#9878;&#65039;</p><p>The red flag is a <strong>mismatch</strong> between two things, and <em>regulators read the whole page</em>: a legal disclaimer that says one thing and a landing page that says another.</p><ul><li><p>The FTC&#8217;s Lumosity case is the classic precedent. In January 2016 the company agreed to <a href="https://www.ftc.gov/news-events/news/press-releases/2016/01/lumosity-pay-2-million-settle-ftc-deceptive-advertising-charges-its-brain-training-program">pay $2 million</a>, after the FTC alleged it claimed its brain games could delay age-related decline and reduce impairment from conditions such as stroke and ADHD. The FTC&#8217;s line: &#8220;Lumosity simply did not have the science to back up its ads.&#8221;</p></li><li><p>In 2022 the FDA sent a <a href="https://www.raps.org/resource/fda-slams-california-company-for-selling-brain-dev.html">warning letter to NeuroField</a>, alleging it marketed neurostimulation and EEG devices without the required premarket approval, clearance or investigational exemption. The company said its devices were biofeedback tools for relaxation training and muscle reeducation, and that it was working with the FDA. Those are allegations and a response, not a finding.</p></li><li><p>A <em>good</em> sign is boring language: what the product <strong>measures</strong>, what it <strong>does not do</strong>, and no disease words</p></li></ul><p>Neither case proves anything about a startup you are evaluating today. &#128373;&#65039; They show how the lane is policed, which is enough to tell you what a careful company avoids saying. &#128678;</p><h2>Red flag 4: the specs are missing, or only the flattering one is shown</h2><p>This audience wants numbers, and honest companies publish them. <strong>Electrode or channel count, signal bandwidth, latency, invasive or not, lead investigator, and stage.</strong> A pitch that says &#8220;advanced AI decodes your brain&#8221; and skips all six is hiding something, or has nothing to hide <em>and</em> nothing to show.</p><p>Beware the single headline number as well, because bigger is <em>not</em> automatically better. &#9888;&#65039; Synchron&#8217;s Stentrode has <strong>16 electrodes</strong> and goes in through a blood vessel, which <a href="https://theroboticsmedia.com/article/synchron-stentrode-pivotal-trial-2026-fda-pma-bci-200-million-series-d">The Robotics Media</a> calls a deliberate trade-off: lower signal fidelity in exchange for a procedure built on routine interventional techniques. A company that explains its trade-offs is one worth taking seriously. &#128300;</p><p>On the consumer side, specs are a useful honesty test. NeurotechMag&#8217;s guide to <a href="https://www.neurotechmag.com/p/you-already-use-neurotech-without">devices you already use</a> describes Neurable&#8217;s MW75 Neuro headphones with <strong>12 dry EEG channels</strong> and a listed bandwidth of <strong>0 to 131 Hz</strong>. A stated bandwidth can be checked, argued over and tested by someone else. &#8220;Proprietary brain score&#8221; cannot.</p><ul><li><p><strong>Ask:</strong> was the metric validated against a clinical-grade reference, and by whom?</p></li><li><p><strong>Ask:</strong> can you export raw data, or is everything locked in an app?</p></li><li><p><strong>Ask:</strong> is the &#8220;focus&#8221; or &#8220;calm&#8221; score described in a peer-reviewed paper?</p></li></ul><p>If the answer to all three is &#8220;trust us,&#8221; that is your answer. &#128161; <em>Would you buy a car on those terms?</em> &#128663;</p><h2>Red flag 5: the privacy policy says more than the science does</h2><p>Brain data is personal in a way most consumer data is not, and its value to a startup is obvious. So check what the company does with the signal <em>before</em> the science is proven. &#128274;</p><p>The Neurorights Foundation reviewed consumer neurotech companies and found that, per <a href="https://kffhealthnews.org/mental-health/colorado-california-montana-states-neural-data-privacy-laws-neurorights/">KFF Health News</a>, <strong>29 of 30</strong> with online products have access to brain data, and that they place no meaningful limits on that access. &#128274; Nearly all can share it with third parties. Colorado passed a neural data law in 2024, California has followed, and Montana&#8217;s took effect in October 2025.</p><ul><li><p><strong>Green flag:</strong> a plain-language policy on who can access raw and derived brain data, and how deletion works</p></li><li><p><strong>Yellow flag:</strong> neural data lumped in with generic &#8220;usage data&#8221; and shared with unnamed partners</p></li><li><p><strong>Red flag:</strong> a product that needs your brain signal to work and a policy that will not say where it goes</p></li></ul><p><a href="https://www.neurotechmag.com/p/7-questions-to-ask-before-buying">NeurotechMag&#8217;s seven-question buying guide</a> covers this too, along with the boring but decisive matters of full 12-month cost and whether the company will still exist in a year. A startup can be sincere and still fail one of these tests. That is <em>fine</em>, so long as you know which one. &#127919;</p><p>So use the five as a filter, not a courtroom. Score each pitch: pathway named, trial findable, claims match the lane, specs published, data terms clear. Which of the five does the next startup in your inbox fail first?</p>]]></content:encoded></item><item><title><![CDATA[A Caregiver's Guide to Neurotech Options for Stroke Recovery]]></title><description><![CDATA[Two FDA-authorized devices, one cleared exosuit, and one stimulation approach that failed its biggest trial: here is what each is, who it is for, and what to ask before you say yes.]]></description><link>https://www.neurotechmag.com/p/a-caregivers-guide-to-neurotech-options</link><guid isPermaLink="false">https://www.neurotechmag.com/p/a-caregivers-guide-to-neurotech-options</guid><dc:creator><![CDATA[NOOCON]]></dc:creator><pubDate>Thu, 08 Oct 2026 05:00:39 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!6heK!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!6heK!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!6heK!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!6heK!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!6heK!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!6heK!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!6heK!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png" width="1456" height="971" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:971,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2325117,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.neurotechmag.com/i/217491872?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!6heK!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png 424w, https://substackcdn.com/image/fetch/$s_!6heK!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png 848w, https://substackcdn.com/image/fetch/$s_!6heK!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png 1272w, https://substackcdn.com/image/fetch/$s_!6heK!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F18438ec0-03dd-45bc-b7e0-85cd8edc2073_1536x1024.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Every stroke caregiver eventually gets the same email from a well-meaning relative: &#8220;Have you seen this brain device?&#8221; &#129504; Some of those devices are real, regulated and sitting in rehab clinics. Others are demos, small trials or wellness gadgets with a stroke photo on the box. Telling them apart is the hard part, and nobody hands you a manual.</p><p>This guide sorts the options by what is proven. I keep three categories apart on purpose: <strong>FDA-authorized rehab devices</strong>, <strong>stimulation methods that have mixed or negative trial results</strong>, and <strong>research-stage implants</strong> that are not available to you. I am not a clinician, and nothing here replaces your neurologist or therapist. It is a map for the conversation you are about to have with them. <em>Which of these has anyone on your care team already mentioned?</em></p><h2>Two devices with an FDA green light for the arm and hand</h2><p>Both of these target the <strong>upper limb</strong> after <strong>chronic</strong> stroke, meaning months or years out, when recovery has usually plateaued. Both need a therapist involved. <em>Only</em> one needs surgery. &#129470;</p><h3>Vivistim: a pulse generator paired with therapy</h3><p><strong>Vivistim</strong>, made by MicroTransponder, is an implanted <strong>vagus nerve stimulation</strong> system. A pulse generator sits in the chest, a lead wire runs to electrodes on the vagus nerve in the neck, and stimulation is timed to rehab exercises. The FDA approved it on <strong>August 27, 2021</strong> for moderate to severe arm and hand weakness after chronic ischemic stroke, as <a href="https://www.hcplive.com/view/fda-approves-vns-system-ischemic-stroke-motor-deficits">HCPLive reported</a>.</p><ul><li><p>Trial: <strong>VNS-REHAB</strong>, the randomized study behind the approval, with <strong>108 participants</strong> (53 active, 55 control)</p></li><li><p>Arm function on the Fugl-Meyer scale: <strong>5 points</strong> gained with VNS versus <strong>2.4</strong> in controls, a 2.6-point gap</p></li><li><p>Response at 90 days (6 points or more): <strong>47.2%</strong> with VNS versus <strong>23.6%</strong> in controls</p></li><li><p>Catch: it is surgery, so the risk-benefit talk belongs with a neurologist and a surgeon</p></li></ul><p>Read those numbers carefully. Almost half responded, which is better than the control group&#8217;s quarter, and it also means more than half did not reach the response threshold. &#128202; That is a real effect and not a miracle. I think honest expectations matter more than hype here.</p><h3>IpsiHand: a brain-controlled glove for home</h3><p><strong>IpsiHand</strong>, from Neurolutions, is a non-invasive <strong>brain-computer interface</strong>. It has three parts: an EEG-based headset, a tablet, and a powered handpiece worn on the hand and wrist. The headset picks up signals from the <em>unaffected</em> side of the brain that relate to moving the weak hand, and the handpiece opens and closes the hand in response. The FDA granted <strong>De Novo</strong> authorization with Breakthrough designation on <strong>April 26, 2021</strong>, for adults doing stroke rehabilitation, and <a href="https://www.neurolutions.com/news/neurolutions-receives-fda-de-novo-market-authorization-for-ipsihand/">Neurolutions says</a> it is designed for home or clinic use. No implant, no surgery. &#127968;</p><p>The randomized trial <a href="https://www.neurolutions.com/news/randomized-controlled-trial-demonstrated-positive-outcomes/">reported by Neurolutions</a> compared 12 weeks of at-home BCI sessions (five per week) with a conventional home exercise program:</p><ul><li><p><strong>62 participants</strong> analyzed (37 BCI, 25 control), on average <strong>5.4 years</strong> after stroke</p></li><li><p>Fugl-Meyer gain of <strong>6.0</strong> points versus <strong>1.5</strong> in controls (p = 0.0007)</p></li><li><p>Clinically meaningful response in <strong>55.5%</strong> of BCI users versus <strong>9.6%</strong> of controls</p></li><li><p>The study was stopped early for efficacy, and the source is the manufacturer&#8217;s own announcement</p></li></ul><p>Those results sound strong. A trial stopped early and summarized by the company still deserves a second look, so ask your clinician for the peer-reviewed paper. Would you be able to commit to five sessions a week for three months?</p><h2>What the wider brain-computer interface evidence looks like</h2><p>IpsiHand is one example of a bigger group of rehab systems that use EEG to detect <em>attempted</em> movement and reward it. Several reviews now pool the randomized trials, including a <a href="https://www.jmir.org/2026/1/e79132">2026 meta-analysis of chronic stroke</a> in the <em>Journal of Medical Internet Research</em>. I could not read the full pooled results, so I will not quote a number. Ask your rehab team what the current reviews say about your loved one&#8217;s stage of recovery. &#128269;</p><ul><li><p><strong>Stage:</strong> several BCI rehab systems are still in trials, and only some are cleared devices</p></li><li><p><strong>Who fits best:</strong> the studies I checked focus on arm and hand recovery, so ask about legs and speech separately</p></li><li><p><strong>What to check:</strong> whether a device is authorized <em>for stroke rehabilitation</em> and not just sold as a general EEG gadget</p></li></ul><p>That last point trips people up. Wellness EEG headbands are sold without FDA review as long as they avoid disease claims, a gap that <a href="https://www.neurotechmag.com/p/5-neurotech-myths-that-are-scaring">NeurotechMag&#8217;s myth-busting piece</a> lays out clearly, and <a href="https://www.neurotechmag.com/p/7-questions-to-ask-before-buying">seven questions to ask before buying a brain wearable</a> is a good checklist for the shop counter. &#128722; A device that does not say <em>stroke</em> anywhere in its FDA paperwork is a wellness product, whatever the ad shows. &#9888;&#65039;</p><h2>The stimulation approach that did not deliver</h2><p><strong>Transcranial direct current stimulation</strong> (tDCS) passes a weak current through scalp electrodes. It is cheap, painless and heavily marketed, and it looks like the obvious add-on to therapy. The best test so far says otherwise. &#9889;</p><p><strong>TRANSPORT2</strong>, a phase 2 trial in <em>The Lancet Neurology</em> (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12758568/">full text on PubMed Central</a>), enrolled <strong>129 people</strong> at 15 US centers. Everyone got 10 sessions of modified constraint-induced movement therapy over two weeks, paired with sham, 2 mA or 4 mA stimulation. The results, as <a href="https://www.emjreviews.com/neurology/news/transcranial-brain-stimulation-fails-to-enhance-stroke-recovery-in-phase-2-study/">EMJ summarized</a>, were:</p><ul><li><p>Sham: <strong>4.91</strong> Fugl-Meyer points</p></li><li><p>2 mA: <strong>3.87</strong> points</p></li><li><p>4 mA: <strong>5.53</strong> points</p></li><li><p>No significant difference between groups (<strong>P = 0.39</strong>), and no safety signal between arms &#128737;&#65039;</p></li></ul><p>So stimulation did not add anything on top of intensive therapy in <em>subacute</em> stroke. The authors call for more work on doses, timing and patient subgroups, which is fair. My take: skip home-built tDCS kits, and treat any stroke-recovery claim for one as unproven. &#128683; The therapy itself, not the current, did the work in that trial. <em>That</em> is the takeaway.</p><h2>Walking, and what is still years away</h2><p>Legs get less neurotech attention, but there is a cleared option. <em>Cleared</em>, though, is not the same as available at your local clinic. The <strong>ReStore Exo-Suit</strong> from Lifeward (formerly ReWalk Robotics) is a soft, powered suit that assists ankle push-off and swing with motors, cables and shoe sensors. <a href="https://golifeward.com/products/restore-exo-suit/">Lifeward lists</a> it as FDA and CE cleared for stroke patients with lower limb disability who can walk at least 1.5 meters with minimal to moderate help, and it is used under a trained therapist in rehab settings, not as a home appliance. &#128694; <em>Supervised</em> means a clinic visit, so ask about travel and schedule. &#128663;</p><ul><li><p><strong>Stage:</strong> cleared for use in supervised rehab</p></li><li><p><strong>Who:</strong> people who already walk with some assistance</p></li><li><p><strong>Not for:</strong> anyone looking for a home device, as far as I can tell from the maker&#8217;s page</p></li></ul><p>Then there is the far end of the field. Implanted speech decoders for people who lost speech after ALS or a brainstem stroke are <em>clinical research</em>, not products, as <a href="https://www.neurotechmag.com/p/how-neurotech-is-giving-people-with">NeurotechMag&#8217;s coverage of paralysis and communication</a> explains. If you follow this space closely, <a href="https://pro.neurotechmag.com/">NeurotechMag Pro</a> members can track every paper, funding round, and trial connected to developments like these, summarized and searchable. &#128200;</p><h2>Questions to bring to the next appointment</h2><p>Bring this list, and write the answers down. &#128221; <em>Ask every question, even the awkward ones.</em> &#128172;</p><ul><li><p><strong>Is this device FDA-authorized for stroke rehab,</strong> or only sold as wellness?</p></li><li><p><strong>How long since the stroke?</strong> Vivistim and IpsiHand data come from chronic stroke, while TRANSPORT2 studied subacute stroke</p></li><li><p><strong>What outcome will we measure,</strong> and by when?</p></li><li><p><strong>Who supervises,</strong> and how many sessions a week can we realistically manage?</p></li><li><p><strong>What is the risk?</strong> Surgery is a very different decision from a headset &#129658;</p></li></ul><p>Two devices have randomized-trial evidence and FDA authorization for the arm. One exosuit is cleared for supervised gait rehab. The main stimulation approach tested so far did not beat sham. Which of those questions do you most need answered <em>first</em>? &#128161;</p>]]></content:encoded></item></channel></rss>